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Abstract
It has been observed and is generally accepted that patients with a given disease
may respond differently to the same treatment. Hence, it is sensible to believe that
there are subgroups of patients, delineated by their biomarker profiles, wherein cer-
tain treatments are better choices than others. However, it is difficult to predict a
priori which patients are good candidates for a given treatment; an ideally designed
trial would adaptively find and update subgroups of patients at an interim analysis
point. We propose a method that does exactly this: ASID, for Adaptive Subgroup-
Identification and enrichment Design. ASID finds predictive biomarkers, estimates
which patient subgroups have differential treatment effects, and modifies the trial
recruitment criteria at an interim analysis point. Moreover, ASID is based on a hier-
archical Bayesian model. In this work, motivated by an Alzheimer’s Disease clinical
trial, we derive and analyze ASID, and compare it to an alternative adaptive enrich-
ment design built around a linear regression model as well as to a random forest based
model (GUIDE). Via numerical simulations, we demonstrate the superiority of ASID.
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1 Introduction
This thesis is concerned with clinical trial design, that is, statistically designed ex-
periments for evaluating the efficacy of new (medical) drugs. In particular, this work
is about an adaptive, Bayesian method for clinical trial design. In this introductory
section, we discuss the basics of Bayesian reasoning and clinical trial design, as well as
why it is sensible to marry the two. We then follow our review of Bayesian principles
with a discussion of adaptive designs and subgroup identification.
1.1 Bayesian Methods
The broadly stated goal of Bayesian inference is to find a posterior distribution for
parameters of interest given data and a particular model. A good overview is Hoff
(2009). The main vehicle toward the goal of obtaining a posterior distribution is
Bayes’ Theorem.
1.1.1 Bayes’ Theorem
Bayes’ theorem is one of the most fundamental laws in probability. It originates
in a posthumously published work by the reverend Thomas Bayes (Bayes, 1763).
The original work was specific to a special case of what we now call the Binomial
distribution, and in 1774, Laplace generalized the theorem and stated it in the modern
form seen today (de Laplace, 1774).
The statement of Bayes’ theorem is as follows. Assume that we have events A
and B, where B has a non-zero probability p(B). Then we have that
p(A | B) =
p(B | A)× p(A)
p(B)
,
where p(A | B) is the conditional probability of A given B.
The utility of this theorem will be apparent throughout this thesis, especially in
the following way. Assume that we have a model Π with parameters θ and some data
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Yn = {y1, · · · , yn}. We have some prior knowledge and beliefs about the parameters
θ given our model Π: we capture this in a prior distribution p(θ|Π). Additionally,
we define the likelihood p(Yn | θ,Π) and probability of the evidence p(Yn | Π). If the







p(θ | Yn,Π) =
p(Yn | θ,Π)× p(θ | Π)
p(Yn | Π)
.
Omitting the dependence on the evidence, we may say that
Posterior ∝ Likelihood × Prior,
or that
p(θ | Yn,Π) ∝ p(Yn | θ,Π)× p(θ | Π).
1.1.2 Bayesian Clinical Trial Design
A general overview of the use of Bayesian methods in medicine is found in Ashby
(2006) and the textbooks Berry et al. (2010) and Spiegelhalter et al. (2004). A theme
until recently was that Bayesian methods were interesting, but never practical because
of their greater computational needs. Hence, while there have been proponents such
as Cornfield (1969) since the 1960s, it was not until recently that meaningful leaps to
implement Bayesian methods were made.
A proponent of Bayesian methods in clinical trial design, Donald Berry, provides
an overview of the advantages of a Bayesian design relative to a frequentist approach
(Berry, 2006). In particular, an earlier work from 2002 suggests that the main avenue
of frequentist criticisms, prior misspecification, is not a serious concern, in the sense
that the error from a misspecified prior is quantifiably small (Berry et al., 2002).
Additionally, some of the advantages pointed out in Spiegelhalter et al. (2004) include
the greater influence of evidence on the reasoning process, explicit modeling of biases,
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and the hierarchical model framework that allows ‘pooling of evidence’ from multiple
sources.
However, there are concerns that are yet unaddressed: between phases of a clinical
trial, whether it is sensible to use prior information, and whether ‘adversarial’ priors
could be chosen by researchers to bias the results toward a company’s financial gain
(Howard et al., 2005). Additionally, Bayesian techniques are unfamiliar and new to
many practitioners, so there are no established standards and thus there is a danger
of misuse stemming from unfamiliarity.
Despite the relative novelty of Bayesian methods in clinical trials, there have
been increasingly many papers and studies based around them. For example, the
work in Thall and Simon (1994) proposed a Bayesian phase II clinical trial design
with a binary outcome. The trial has two stopping conditions: when the treatment
under investigation has a high posterior probability of being promising or not being
promising, or when the maximum sample size is reached. One of the strengths of this
approach is being able to terminate an inconclusive or unfruitful trial early.
Another interesting work is Simon (1999). This study compares an ‘experimental
treatment’ to a control, and derives the posterior probability that the experimental
treatment is superior to a placebo and the control (with varying degrees of superior-
ity), and that the control is superior to the placebo. The idea behind this approach is
that the frequentist method of conducting a hypothesis test with some cutoff is arbi-
trary, since the choice of cutoff is itself arbitrary in the absence of knowledge of how
much more effective than the placebo the control treatment is. Instead, quantifying
the evidence for the effectiveness of each treatment is a more quantitative approach.
Finally, a well-known, real clinical trial is the I-SPY 2 breast cancer trial (Barker
et al., 2009). This trial effectively made use of biomarker data, and compared two
groups given a standard chemotherapy treatment (control) with five groups given
different, new drugs in addition to the chemotherapy. The design of the trial was
adaptive, and formed assignments based on the biomarker profiles and drug suc-
cess relative to biomarker profiles. Additionally, drugs with universally low posterior
probabilities of success were dropped, while those with a high posterior probability
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of being more successful than the control would ‘graduate’ to a phase III trial.
1.1.3 Markov Chain Monte Carlo
Markov Chain Monte Carlo (MCMC) methods are a class of numerical methods for
sampling from otherwise intractable distributions. For example, we may know the
shape of a distribution but not the normalizing constant. Or, we may know the
density function, but the function is complicated and there is no easy way to form
the distribution function and/or invert it. This class of methods was introduced by
Hastings in 1970 (Hastings, 1970). An important development came in 1984 with
Gibbs sampling (Geman and Geman, 1984).
MCMC methods are essential for practical Bayesian inference. Often, we do not
know the normalizing constant of a posterior distribution, and even more often, we
cannot sample from a posterior distribution directly, to say nothing of computing
statistics of interest like the posterior mean or median. The development of faster
and better computers from the 1990s onward and some mainstream practical imple-
mentations of MCMC methods in recent years have contributed to the acceleration
of practical Bayesian inference.
We conclude this discussion of MCMC techniques with an overview of the algo-
rithm we use in our numerical simulations: the Metropolis-Hastings sampler (Robert
and Casella, 2013). Formally, the goal is to sample from a distribution with probabil-
ity density p(x). However, we only have knowledge of f(x), where f(x) is proportional
to p(x). Assume that we desire M total samples, and have chosen a proposal distri-
bution with density g. Assume further that we discard the first B samples (burn-in)
to ensure convergence to the stationary distribution and thereafter only keep every
T th sample to ensure that the samples are decorrelated. Then, the algorithm is as
follows:
MH.1 Choose an initial state x randomly within the support of f(x) (which is
the same as that of p(x)).
MH.2 Sample a new state x′ from a proposal distribution with density g(x′ | x).
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The density g can be thought of as the probability of moving to a state x′
conditioned on the previous state being x.
MH.3 Form the acceptance distribution
A(x′ | x) ∝ f(x′)× g(x | x′)
and
A(x | x′) ∝ f(x)× g(x′ | x)





f(x′)× g(x | x′)
f(x)× g(x′ | x)
.
MH.4 Accept and store the state x′ with probability min{α(x, x′), 1}.
MH.5 When B + TM states have been accepted and stored, proceed to Step
MH.6. Otherwise return to Step MH.2.
MH.6 Discard the first B stored states, and then discard all but every T th state
so that there are M states (samples) returned.
Details on the exact implementation of this algorithm for the work found in this thesis
are given in Appendix G.
1.2 Subgroup Identification
Often, the same treatment will react differently in two patients with the same disease.
That is, the response to a treatment varies across some latent subgroups of patients,
where these subgroups are characterized by the patients’ physiological characteristics:
biomarkers. If the same treatment can lead to significantly different responses in
two patients with the same disease, a clinical trial should in addition to evaluating
the efficacy of the treatment, characterize for which patients it is effective. Simply
put, a clinical trial should also identity the patient subgroups wherein a treatment
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is effective. Equivalently, a trial should find which biomarkers and which values of
those biomarkers are predictive of treatment success.
An example of how and why subgroup identification is important is found in a
recent study of breast cancer patients (Hudis, 2007). It was found that the medication
trastuzumab is only a good choice for patients with an ‘enriched HER2 pathway’. In
this study, the conclusion was that matching certain genetic traits (biomarkers) to
various treatments was optimal. A second example of subgroup identification is found
in a study of patients with colorectal cancer (Misale et al., 2012). In particular, the
study found that patients with KRAS mutated colorectal cancer should not be given
treatment with EGFR antibodies. These real examples showcase the importance of
subgroup identification.
A flagship frequentist method that we will compare our methods against is GUIDE
(Loh et al., 2015). GUIDE is a regression tree-based method, wherein variable se-
lection via χ2-tests identifies which variables to split on, and the splits yield the
subgroups which have differential treatment effects. The work in Shen and He (2015)
is related, and used a structured logistic-normal mixture model to form tests to con-
firm the existence of subgroups. These methods are not specific to clinical trials,
and indeed have not been applied directly in this setting: they are general subgroup
identification methods.
Perhaps the most immediate starting points for this work are SUBA (Xu et al.,
2014) and its extension SCUBA (Guo et al., 2016). SUBA is a Bayesian Subgroup-
Based Adaptive design wherein a random partition model (akin to a tree) partitions
the patient biomarker space by splitting along the median of the observed values. The
goal of the partitions is to find an allocation of patients to their optimal treatment.
However, the median is often suboptimal and is a priori an arbitrary choice. The work
in SCUBA allows for general affine hyperplanes to serve as split boundaries. However,
both works are non-adaptive in the sense that the entry criteria is not modified.
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1.3 Enrichment Design
As explained in the previous section, it is important for a clinical trial to identify
fruitful subgroups for a treatment. However, clinicians may not be aware of the
treatment’s precise mechanism or even the disease’s biochemical characteristics in
great detail. Hence, if a clinical trial could adaptively change how it recruits patients
to more efficiently find the ideal patient biomarker ranges for the treatment under
investigation, the chances of success would increase. Methods to do precisely this,
modification of the entry criteria at the interim analysis stage, have been developed.
Authors in the field term patients with the desired, positive treatment response as
“enriched”. A recent survey of adaptive designs in real clinical trials is given in
Hatfield et al. (2016). The paper is a meta-analysis of recent trials, and showed that
the use of adaptive designs is increasing, especially in oncology.
Some prior work in the area is Wang et al. (2007) and Karuri and Simon (2012).
Both works are adaptive in the sense that they began with subgroups defined in
terms of biomarkers, and at the interim analysis, halted enrollment of patients from
the less successful (biomarker negative) subgroups. Additionally, Rosenblum and
van der Laan (2011) described an adaptive trial design wherein pre-planned, pre-
designed criteria were used to alter entry criteria. The work in Simon and Simon
(2013) furthered a series of adaptive updates to the eligibility criteria. The strength
of this work lies in the control of the type-I error. The paper Wang and Hung (2013)
contains a more detailed survey of adaptive enrichment designs.
The body of work we have just described is not truly adaptive, in the sense that it
uses pre-drawn subgroups. This approach may lead to poor outcomes if the subgroups
are poorly chosen and are not correlated with treatment outcomes or treatment as-
signments. Hence, a high quality, truly adaptive enrichment design should include
methods for subgroup identification. For example, the work in Sivaganesan et al.
(2011) uses a model selection procedure (variable selection on the biomarkers) to find
subgroups, and the work in Foster et al. (2011) uses a random forest algorithm to
to find regions of the biomarker space where the treatment has a larger-than-average
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effect relative to the whole space. Another approach is SIDES, (Lipkovich et al.,
2011). SIDES (subgroup identification based on differential effect search), uses a
Classification and Regression Tree (CART) (Breiman et al., 1984) to find bisections
of the biomarker space wherein the halves have maximally different effect sizes. A
very recent work is Trippa et al. (2012), where Bayesian methods for enrichment are
studied in the context of a renal cell carcinoma oncology trial. A Bayesian decision-
theoretic perspective is used to parametrize a random discontinuation design wherein
the results from a first stage are used to identify a subpopulation to enrich.
1.4 A Biomarker-Driven and Subgroup-Based Enrichment
Design
This thesis contains a proposed class of adaptive subgroup-identification enrichment
designs (ASID). The design uses patient biomarker profiles and patient treatment
outcomes as they are found. The ASID algorithm adaptively finds subgroups in the
space of biomarkers instead of predefining them. The design allows the clinical en-
try criteria to be updated in the course of the trial, so that patients who are more
likely to respond to the treatment are selected. This choice improves the prospects
for finding a clinically significant treatment effect. Additionally, our design is built
around a hierarchical Bayesian model: our model is extremely flexible and can handle
biomarkers (covariates) of different domains (continuous, binary, categorical, ordinal)
and responses (outcomes) of different forms (binary, categorical, continuous, regres-
sion).
The ASID algorithm is a novel approach to clinical trial design. It pushes the
envelope by its ability to continuously identify and update subgroups of patients with
differential treatment effects. Additionally, it is a Bayesian approach. Our approach
is superior to preexisting takes on this problem: we only need data from one trial,
and we can handle low sample sizes since we adaptively recruit patients in a manner
that optimizes the chances of finding a differential treatment effect. Moreover, our
approach is far more flexible as a consequence of being adaptive.
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1.5 Motivating Trial
The work in this thesis is motivated by a study for a new compound for treating
patients with Alzheimer’s disease (AD). The study is a double-blind, proof-of-concept
(POC) trial, with a placebo as control. The quantitative goal of the study is to effect
a beneficial change in patients with AD from their initial baseline measurements,
as measured by the 13-point AD Assessment Scale–Cognitive Subscale (ADAS-cog)
score.
Prior work in the area (for example, Cummings et al. (2012)) suggests that there
are several physiological quantities (biomarkers) that may be good predictors of treat-
ment efficacy. Among other quantities, these biomarkers include apolipoprotein E
(APOE)-ϵ4 genotype and allele status, plasma amyloid precursor protein β (Aβ),
and cerebrospinal fluid (CSF) β-site amyloid precursor protein (APP)-cleaving en-
zyme 1 (BACE1). However, it is possible that the compound under investigation is
only effective for certain ranges of one or more biomarkers. That is, there may be
subgroups of the population wherein the investigational compound is effective (in a
clinically meaningful sense), and outside of which it is less effective (if effective at all).
Hence, the goal herein is to marry the tasks of identifying fruitful patient subgroups
and population enrichment with the goal of rapid development and investigation of
this new compound.
This study proceeds as follows. Patients diagnosed with AD who meet certain
clinically given entry criteria will be selected and equally randomized to the placebo
or investigational compound. Biomarker data (baseline) will be collected at the start,
and at the pre-determined point of the interim analysis, the ADAS-cog scores will be
used to find potential subgroups of patients wherein there is a differential treatment
effect. If and when such a subgroup is found, the entry criteria will be altered to only
accept new patients whose biomarker data places them within the subgroup. In this
way, the study allows for population enrichment within the trial, so that more high




This thesis is organized as follows. We describe the Bayesian probability models in
Section 2. In Section 3, the proposed design (characterized above) is summarized.
In the next section, Section 4, we present comprehensive simulation studies and sta-
tistical properties of the ASID design. We conclude with Section 5. We defer many
technical details and tables of numerical results to the appendices.
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2 Probability Model
In this section, we begin by discussing the sampling model, and then follow up with
the construction of partitions of the biomarker space to find the patient subgroups.
2.1 Notation
We first define some notation. There are at mostN patients, labeled by i ∈ {1, . . . , N},
T treatments labeled by t ∈ {1, . . . , T} (the motivating AD trial uses T = 2), and K
biomarkers labeled by k ∈ {1, . . . , K}. Let zi be the treatment label for patient i. Let
xi = (xi1, . . . , xiK)
′ denote the biomarker profile for patient i, where xik is the value
of biomarker k for patient i. The biomarkers may be continuous, ordinal, binary, or
categorical. The response for patient i is denoted by yi. We will explicate our model
based upon the domain of yi.
Let Ω be the biomarker space, and let the variable Π denote a partition. A parti-
tion is a family of mutually disjoint subsets of Ω whose union is Ω: Π = {S1, . . . , SM}.
Let M be the number of subsets in Π, where M is a random variable. Given a par-
tition of the biomarker space, we naturally induce one on the collection of patients.
The relationship is the following: if xi ∈ Sm, we say that patient i belongs to the
subgroup with label m.
2.2 Sampling Model
Consider now the sampling model. We divide our explanation into the various cases
for the support of yi.
2.2.1 Binary Outcomes
Binary outcomes are perhaps the simplest, most intuitive sort of outcome: a treatment
is successful or it is not. Let yi ∈ {0, 1} and let θt,m denote the response rate of patients
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in subgroup m with treatment t. That is, we assume that
p(yi = 1 | xi ∈ Sm, zi = t,Π) = θt,m.
Here, the likelihood function is the product of n Bernoulli probability mass functions.
The conjugate prior on θt,m|Π is a Beta distribution. We use the notation Beta(a, b),
where this denotes a Beta distribution with mean a/(a+ b). The details are found in
Appendix C.
2.2.2 Categorical Outcomes
Categorical outcomes extend the binary case to more gradations. Note that binary
outcomes are a special case of categorical outcomes with C = 2. Indeed, the two
types have very similar specifications. Let yi ∈ {1, 2, . . . , C}, where C is a finite,
positive integer. Let θc,t,m denote the response rate of patients in subgroup m with
treatment t and response c. That is, assume that
p(yi = c | xi ∈ Sm, zi = t,Π) = θc,t,m,
and that the likelihood is a product of categorical distribution probability mass func-
tions. Moreover, we constrain the θc,t,m so that
∑C
c=1 θc,t,m = 1. The conjugate prior
on (θc,t,m)
C
c=1 | Π is a Dirichlet distribution with parameters (ac)
C
c=1. The details are
found in Appendix D.
2.2.3 Continuous Outcomes
For continuous outcomes, let yi ∈ R and let θt,m be the average (arithmetic mean)
of the patient responses in subgroup m with treatment t. Assume that the responses
are conditionally normal, or that
p(yi | xi ∈ Sm, zi = t,Π) = N (θt,m, σ
2),
12
where the notation N (a, b) denotes the probability density function for a Gaussian















The conjugate prior for θt,m and σ
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). In the previous expression, SS20 =
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0 and IG(a, b) denotes the density function for an Inverse Gamma distributed
random variable with shape parameter a and rate parameter b. Here, θ0, κ0, ν0, and
σ20 are hyperparameters. The details are found in Appendix E.
2.2.4 Linear Regression Model
Consider a variant of continuous outcomes, wherein yi is a linear transformation
of the biomarker vector xi: yi = x
′
iβt,m + ϵi, where βt,m is the linear regression
coefficient vector for patients in subgroup m with treatment t. We let ϵi ∼ N (0, σ
2),
where N (a, b) denotes the Gaussian distribution with mean a and variance b. We use
conjugate priors on βt,m and σ
2: βt,m ∼ N (µ0,Σ0) and σ
2 ∼ IG(a0, b0). Under this
setup, the posterior distributions of βt,m and σ
2 are multivariate normal and inverse
Gamma distributions, respectively. The details are found in Appendix F.
2.2.5 Joint Model
Let Θ denote the parameters in the sampling model. Furthermore, let Yn = (y1, . . . , yn),
Xn = (x1, . . . , xn), and Zn = (z1, . . . , zn). We can now package the sampling models
and priors in one expression:
p(Yn,Θ,Π | Xn,Zn) ∝ p(Yn | Xn,Zn,Θ,Π) p(Θ | Π) p(Π | c)p(c), (2.2)
where we use c to represent the model parameters describing the partition Π. The
details for each expression depend on the response type, and can be found in the
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immediately preceding sections.
2.3 The Partition Π
In this section, we describe the construction of the partition Π. Here, we will focus
on the intuition and give a general characterization. In Appendix A, we present a
detailed examination of the construction. Additionally, in Appendix B, we present a
brief combinatorial characterization of the partitions.
We begin with the biomarker space Ω, and choose a biomarker k and a threshold
τk for the first split. The choice of a threshold τk bisects Ω into two disjoint subsets:
the first subset contains all points in Ω with biomarker k (coordinate k) smaller than
or equal to τk, and the second subset contains all other points. In the case that
biomarker k takes categorical values (discrete with no ordering), τk is a subset of
values, and we have one subset given by points in Ω with biomarker k valued in τk
and the other by those points with biomarker k not in τk.
After the first split, we have two subsets. For the second split, we bisect each of
the subsets in a similar manner to the first split. That is, within the first subset, we
split along a threshold τk1 in biomarker k1, and within the second, we split along τk2
in biomarker k2.
It is important to note that at any stage, we have the option to stop splitting.
That is, at the first stage we may not split at all and return Ω as the partition.
Moreover, at the second stage, we may choose to split within only one or even none of
the subsets from the first stage. In this way, from two rounds of splitting, we may form
1, 2, 3, or 4 subsets of Ω. This procedure is naturally extensible to multiple rounds
of splitting: given any subset, the splitting rule is simply to choose a biomarker and
a threshold, and then to bisect the subset along the threshold. In this work, we limit
ourselves to two rounds of splitting, as in the motivating AD trial. This constraint
limits the incidence of subgroups containing relatively few patients.
Our construction of the partition has a natural structure: that of a tree. Let each




In this section, we discuss the trial design for a continuous outcome with two treat-
ments (one placebo and one compound under investigation) and one interim analysis.
While this setup mimics the motivating AD trial, we could easily extend our analysis
to several treatments and several interim analyses, and to other response types.
The goal of the interim analysis is to learn which regions of the biomarker space
Ω yield promising candidates for the compound under investigation. However, the
partition is a random variable with a distribution. We must hence be creative in how
we report our results. Assume that we have biomarker and response data from N
patients, and let DN = {YN ,XN ,ZN} be the response, biomarker, and treatment
data. Assume further that we have posterior samples of Π(b) = {S(b)m }Mm=1 from a
Markov Chain Monte Carlo (MCMC) simulation. Next, we construct a grid in Ω. In
each biomarker k, we let Dk be a finite, positive integer and choose Dk evenly spaced
points in the domain of biomarker k. We then take the Cartesian product of these
sets to yield the final grid. Then, each grid point d has a biomarker profile xd given by
its coordinates. From the MCMC data, we can iterate over the posterior samples Π(b)
and assign d to a subgroup S
(b)




for point d under treatment zd to the subgroup response under the same
treatment, θ
(b)
zd,m. After repeating this procedure for each grid point and treatment,
we have an array with values of θ for each grid point under each treatment from each
posterior sample of Π.
We have assumed that T = 2, that is, that there are two treatments: placebo






1,d be the difference between
the response under the compound and placebo. This quantity is the treatment ef-
fect. If there are B posterior samples (after burn-in, discarding, et cetera), we can
approximate the posterior probability of a patient with biomarker profile xd having
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where Ia is the indicator for the event a (taking value 1 if a occurs, and 0 otherwise).
The LRV is a clinically given quantity, and is the minimum increment between two
treatments’ effects that is meaningful.
Now that we have specified the background information and notation, we describe
how our trial, ASID, will be conducted.
1. The start of the trial. The first n patients are equally randomized to both
treatment groups (placebo, investigational compound).
2. The interim analysis. Let ∆ be the convex hull (smallest possible convex su-
perset) of the set {d : ξd ≥ δ} for some threshold δ (Graham, 1972).
• If ∆ is non-empty, we restrict the recruitment of new patients into the
trial to patients with biomarker profiles xi contained in ∆. We equally
randomize the additional N − n patients to both treatment groups.
• If ∆ is empty, we end the trial.
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4 Simulation Studies
In this section, we perform numerical experiments to demonstrate the performance
of our algorithm, ASID.
4.1 Simulation Setup
The setup herein mimics the motivating AD trial. Our goal is to evaluate the perfor-
mance of the ASID relative to other methods. We simulate from K = 4 biomarkers
and assume a uniform prior for splits on these biomarkers: p(νk) = 1/(K + 1). The
priors on the other parameters c are given in Appendix A. We assume that there
is a initial phase with n = 80 patients, wherein all patients are equally and uni-
formly assigned to the placebo and compound under investigation. In every trial, the
maximum sample size is capped at N = 140 patients.
We compare our method, ASID, with a linear regression (LR) model. In the LR
setup, we model the responses with a Bayesian linear regression wherein we include
all solo effects and the interactions between the treatment and biomarkers. That is,
yi | zi,xi = β0 + β1zi +αxi + γzixi + ϵi, (4.1)
where the ϵi are i.i.d. centered Gaussians with variance σ
2. We place non-informative
conjugate priors on β and σ2: β is given a multivariate normal prior with mean zero
and covariance 20I, and σ2 has an inverse Gamma prior with parameters (0.1, 0.1).
We use a Gibbs sampler to find posterior samples, from which we compute
q
(b)
d = E(yi | zi = 1,xd)− E(yi | zi = 0,xd).
We also compare our method with GUIDE (Loh et al., 2015). We fit a GUIDE
random forest linear regression model 200 times for each set of patient data. Each
constructed random forest is based on ten trees each and uses no more than three
split levels. We let a patient’s assigned treatment be considered a categorical variable
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in an effort to use all biomarkers as well as the treatment assignment as variables for
splitting. For an ensemble method such as random forest, GUIDE does not explicitly
report subgroups, so we compute treatment effects over a grid.
We vary the LRV, the clinically meaningful threshold for the effect sizes. Note
that 2.37 is the LRV that represents the average performance of marketed drugs,
and an LRV above 2.37 indicates that there is a gain worth pursuing; 3.08 is the
TRV, or the Targeted Reference Value for a new compound. For convenience, we use
LRV for both LRV and TRV. Additionally, we vary both the stopping point in the
enrichment design and the threshold δ for the minimum posterior probability of the
treatment effect being larger than the LRV. When this occurs for a grid point with a
particular biomarker profile xd, we say that this grid point belongs to the ‘successful
subgroup’, that is, a latent subset of grid points (patients) who respond positively to
the investigational compound.
4.2 Scenarios
There are six scenarios that we consider. These scenarios are depicted in Figure
2. The figure shows the regions where treatment 2 (the investigational compound)
outperforms treatment 1 (the placebo). Note that there are K = 4 biomarkers: there
are two additional biomarkers that we do not (and cannot) plot. We assume that these
biomarkers have no bearing on the treatment outcome and that they are continuously
valued with domain [−1, 1].
Formally, we model the scenarios as follows. We let the response yi be generated
as follows:










0.75 if zi = 1,
1.0 if zi = 2 and xi /∈ Rs
1.0 + E if zi = 2 and xi ∈ Rs,
where E is our effect size (set to 3.5) and Rs is the ‘active region’ for treatment 2
under scenario s. The phrase ‘active region’ refers to the region of the biomarker
space where treatment 2 outperforms treatment 1. We use ϵi to denote a standard
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Gaussian random variable (mean 0 and variance 1). The regions Rs are described in
Table 1.
Scenario Domain of x1 Domain of x2 Rs
1 [−1, 1] [−1, 1] x2 ≤ 0.4 and x1 ≤ 0.4
2 [−1, 1] [−1, 1] x2 ≥ −0.4
3 [−1, 1] [−1, 1]
x2 ≥ 0, or,
x2 < 0 and x1 ≥ 0
4 {0, 1} [−1, 1] x2 ≤ 0.4 and x1 = 0
5 {0, 1} {1, 2, 3}
x2 = 1 and x1 = 0, or,
x2 ∈ {2, 3} and x1 = 1
6 {1, 2, 3, 4} {1, 2, 3}
x1 = 1, or,
x1 = 3, or,
x2 ≤ 2 and x1 ∈ {2, 4}
Table 1: The scenario truths and regions where treatment 2 outperforms treatment
1.
4.3 Simulation Metrics
Let ξhd be the posterior probability that the treatment effect in trial h from grid point
d with biomarker profile xd is larger than the LRV. From 100 trials, we computed







where δ is the threshold for a success and is varied between 0 and 1.
Furthermore, we report the True Positive Rate (sensitivity) and the True Negative
















I(xd /∈ ∆̂)/(|Ω \ S
o| × 100).
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Note that the TPR and TNR are between 0 and 1, and in the ideal case are equal to
1.
Finally, we study the effect of enrichment in ASID. We compare modifying the
study entry criteria at the interim analysis with not doing so (the WO design). Let
yhi be the response and z
h
i be the treatment assignment for patient i in trial h. We































This quantity is the average of the treatment effects between the two treatment groups
after the interim analysis at the end of the trial. We want this value to be as large as
possible. We compare the effect sizes from recruiting from all subgroups (ALL) with
recruiting from only the subgroup wherein a significant treatment effect was detected
(SUB).
Finally, we study whether under a truly null scenario, we recover a null result.
We notate this by SFE (subgroup found error), and in the ideal case, it is equal to 0.
4.4 Results
We present our results in tabular form in Appendix H. Theses tables are separated
first by scenario, and second by the value of the threshold δ. Within each table, we
vary the number of patients and the LRV. All three methods are compared side-by-
side. We also present figures for δ = 0.9 and the LRV equal to 2.37 and 3.08.
The simply stated conclusion from these numbers and figures is that our method,
ASID, outperforms GUIDE and a linear regression in the best case, and has perfor-




In Scenario 1, shown in Figure 3, ASID outperforms GUIDE for lower patient num-
bers, before GUIDE ‘catches up’ at 140 patients. In Scenario 2, shown in Figure 4,
ASID and GUIDE are comparable for low LRV, but ASID noticeably outperforms
GUIDE for high LRV. In Scenario 3, shown in Figure 5, we have the same trend
as in Scenario 2. In Scenario 4, shown in Figure 6, ASID outperforms GUIDE for
low patient sizes. Interestingly, GUIDE appears to exhibit a phase transition type
behavior as the number of patients increases. In Scenario 5, shown in Figure 7, ASID
outperforms GUIDE. Finally, in Scenario 6, shown in Figure 8, ASID and GUIDE
are generally comparable. In all Scenarios, the linear regression (LR) performs worse
than ASID and GUIDE.
4.4.2 TNR
The TNR values for all algorithms and LRV values are comparable and close to 1,
except in Scenario 3, shown in Figure 5. The ASID TNR values lag behind both
those of GUIDE and the linear regression for smaller patient sizes, and are closer but
still lower at higher patient sizes.
4.4.3 SFE
The SFE for all algorithms and LRV values is essentially zero.
4.4.4 Effect Sizes
The last comparison we make is that of the effect sizes under enriched v. non-enriched
scenarios. In Scenario 1, shown in Figure 3, the enrichment design leads to a higher
effect size for all patient sizes and algorithms. In Scenario 2 (Figure 4), 3 (Figure
5), 4 (Figure 6), and 5 (Figure 7), we have the same result. In Scenario 6, shown
in Figure 8, the effect size values from the enrichment are greater than those from
without the enrichment, except for a few patient sizes with the GUIDE algorithm.






In this thesis, we have proposed, derived, implemented, tested, and analyzed a novel
method for clinical trial design. Our method is adaptive and is an enrichment design.
Additionally, it is built around a hierarchical Bayesian model. The method allows for
adaptive identification of subgroups with differential treatment effects, and adaptive
modification of trial entry criteria. One key contribution of our method, ASID, is the
random partition model and an MCMC algorithm for sampling from the posterior
distribution of this model.
The principal takeaway of this work is demonstrated conclusively in the numerical
simulations. ASID effectively and successfully recovers the subgroups depicted in the
simulation truth, and relative to GUIDE and a linear regression design, has stronger
statistical performance.
Future work on this project would extend ASID to the scenario where there are
many biomarkers, and variable selection must be performed at each stage. Addition-
ally, a simple extension would include an adaptive patient allocation scheme, wherein
patients would be assigned to their optimal treatments, and a ‘favorable’ or ‘optimal’
patient subgroup to recruit from for a later phase III trial would be specified.
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Appendix A Partition
In this section, we describe the rules for forming a partition of the biomarker space
Ω. We assume that there are two rounds of splits, and that the covariates may have
continuous, binary, categorical, or ordinal domains. We assume that there are K
biomarkers, indexed by {1, . . . , K}, and that the letter k is used to index biomarkers.
The letter c will be used to index the thresholds or split locations. We will use xi to
denote an arbitrary biomarker vector with kth coordinate xik.
A.1 The First Split
We first choose a biomarker k to split on. We assume that we choose a biomarker k
with probability νk = 1/(K+1), and that we may choose not to split with probability
ν0 = νk. That is, there is a uniform prior on k. We next choose the location of the
split ck, so that we split the biomarker space Ω into two subsets, Lk and Uk.
• If we choose not to split, we are done: ck is irrelevant. We may set ck = ∅, and
assume by convention that p(ck | k) = 1.
• If the biomarker k is binary valued, the split is deterministically given: there
is only one option. We let Lk = {xi : xik = 0} and Uk = {xi : xik = 1}, and
p(ck | k) = 1.
• If the biomarker k is continuous, we let Lk = {xi : xik ≤ ck} and Uk = {xi :
xik > ck}. We let p(ck | k) be uniformly distributed on the observed domain




i=1). If the support of
biomarker k is [−1, 1], p(ck | k) = 1/2.
• If the biomarker k is ordinal valued, let Vk be the number of distinct values of
biomarker k, where the set of values is {1, . . . , Vk}. Let ck denote the endpoint
of the ‘left’ partition, i.e., Lk = {xi : xik ≤ ck} and Uk = {xi : xik > ck}.
We constrain ck to be smaller than Vk: if ck = Vk, we are not splitting, which
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is a previously considered event. We assume a uniform prior on ck, where
p(ck | k) = 1/(Vk − 1). Note that if Vk is 2, we are exactly in the binary setting.
• If the biomarker k takes discrete values without any further structure, we say
that it is a categorical variable. Let this variable take values in the set Ck =
{1, . . . , Vk}. We will use ck to represent one subset of Ck, so that Lk = ck and
Uk is the complement of ck, or Ck\ck. Note that if ck is equal to ∅ or Ck, we are
not splitting. Hence, ck is valued in the powerset of Ck, without the elements ∅
and Ck. Thus, if we choose a uniform prior for ck, p(ck | k) = 2/(2
Vk − 2). The
extra factor of 2 comes from the symmetry between Lk and Uk: choosing ck or
its complement leads to the same partition.
A.2 The Second Split
We now discuss the second split. If we do not split in the first round, there is no
second split. If we do split in the first round, we have two subsets: Lk and Uk. We
split again within each subset. There is also the option of not splitting within one or
both subsets. Assuming that we split within both subsets, we choose biomarker k1
for the split within Lk and k2 for that within Uk, and give both the same priors as k.
If we split within Lk, we choose a threshold ck1 to form LLk,k1 and LUk,k1 . Similarly,
we form ULk,k2 and UUk,k2 using threshold ck2 .
We now discuss how to form ck1 and ck2 . We describe the structure of the subsets,
and then describe the priors.
• No split:
1. If we do not split within Lk, ck1 = ∅ and we say that p(ck1 | k, k1) = 1.
2. If we do not split within Uk, ck2 = ∅ and we say that p(ck2 | k, k2) = 1.
• Binary Biomarkers:
1. If biomarker k1 is a binary valued variable, let LLk,k1 = {xi : xi ∈
Lk, and xik1 = 0} and LUk,k1 = {xi : xi ∈ Lk, and xik1 = 1} with
p(ck1 | k, k1, ck) = 1.
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2. If biomarker k2 is a binary valued variable, let ULk,k2 = {xi : xi ∈
Uk, and xik2 = 0} and UUk,k2 = {xi : xi ∈ Uk, and xik2 = 1} with
p(ck2 | k, k2, ck) = 1.
3. Note that k = k1 or k = k2 are nonsensical options here.
• Continuous Biomarkers:
1. If biomarker k1 is continuous and k ̸= k1, let LLk,k1 = {xi : xi ∈
Lk and xik1 ≤ ck1} and LUk,k1 = {xi : xi ∈ Lk and xik1 > ck1}. We
have that p(ck1 | k, k1, ck) is uniform on the domain of biomarker k1. If the
support of biomarker k1 is [−1, 1], p(ck1 | k, k1, ck) = 1/2.
2. If biomarker k1 is continuous and k = k1, the above setup holds, but
p(ck1 | k, k1, ck) is uniform on the range of Lk, that is {xi : xi ≤ ck}. If
the support of biomarker k is [−1, 1], p(ck1 | k, k1, ck) = 1/(1 + ck).
3. If biomarker k2 is continuous and k ̸= k2, let ULk,k2 = {xi : xi ∈
Uk and xik2 ≤ ck2} and UUk,k2 = {xi : xi ∈ Uk and xik2 > ck2}. We
have that p(ck2 | k, k2, ck) is uniform on the domain of biomarker k2. If the
support of biomarker k2 is [−1, 1], p(ck2 | k, k2, ck) = 1/2.
4. If biomarker k2 is continuous and k = k2, the above setup holds, but
p(ck2 | k, k2, ck) is uniform on the range of Uk, that is {xi : xi > ck}. If
the support of biomarker k is [−1, 1], p(ck2 | k, k2, ck) = 1/(1− ck).
• Ordinal Biomarkers:
1. If biomarker k1 takes ordinal values and k ̸= k1, let ck1 denote the left
endpoint of the second split within Lk. We have a uniform prior p(ck1 |
k, k1, ck) =
1
Vk1−1
. We form LLk,k1 and LUk,k1 analogously to how Lk and
Uk were formed.
2. If biomarker k1 takes ordinal values and k = k1, the above holds, except





3. If biomarker k2 is ordinal valued and k ̸= k2, let ck2 denote the left endpoint




ULk,k2 and UUk,k2 analogously to how Lk and Uk were formed.
4. If biomarker k2 takes ordinal values and k = k2, the above holds, except





1. If biomarker k1 takes categorical values and k ̸= k1, let ck1 denote the
left subset of the second split within Lk. We have a uniform prior p(ck1 |




, exactly as we did on ck. We form LLk,k1 and LUk,k1
analogously to how Lk and Uk were formed.
2. If biomarker k1 takes categorical values and k = k1, the above holds, except
that p(ck1 | k, k1, ck) =
2
2|ck|−2
, where |A| denotes the cardinality of the set
A.
3. If biomarker k2 is categorically valued and k ̸= k2, let ck2 denote the left





we form ULk,k2 and UUk,k2 analogously to how Lk and Uk were formed.
4. If biomarker k2 takes categorical values and k = k2, the above holds, except





Appendix B A Combinatorial Aspect of Subgroup
Generation








This is an elementary combinatorial identity for the partial sums of a geometric
series. Interestingly, this identity has a natural connection to our method of obtaining
subgroups and creating the partitions described in Appendix A.
Let there be N biomarkers and at most r rounds of splits. Our claim is that the
quantity







is the number of possible subgroups modulo the thresholds. That is, if we solely
characterize subgroups by which variables were split on and whether they are greater
than or less than some threshold, this quantity is the number of possible subgroups.
Before delving into the justification of our claim, we given an example to explain
what we mean by subgroups modulo thresholds. Our notation to label the subgroups
is as follows. We will use the number (N + 1) to indicate that we do not split in a
given round. Following a biomarker index, we will use 0 to indicate the left (below
the threshold) subgroup and 1 to indicate the right (above the threshold) subgroup;
after (N + 1), we use (N + 1) in place of 0 or 1. Our example has N = 2 continuous
biomarkers. If we do not split, we have the whole space as a single subgroup, which
we notate by 33. If we split along biomarker 2 and then do not split further, we have
two subgroups: 20 and 21. If we split along biomarker 2, and then in the ‘left’ section
split again along biomarker 2 and split along biomarker 1 in the ‘right’ section, we
have 4 subgroups. The subgroups are labeled by 2020 (left within left), 2021 (right
36

length. Hence, if we know that there are at most r rounds of splits, we may pad our
character strings with (N + 1)s so that all subgroups have labels of length 2r.
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Appendix C Binary Response Model
In this section, we report the details of the model for patients with a binary response.
We begin with some notation. Let n denote the total number of patients. Let
nmt denote the number of patients in subgroup m receiving treatment t. Let nmt1
be the number of patients in subgroup m receiving treatment t with response 1, and
similarly for nmt0. Let Yn denote the collection of all patient responses Yi. Note
that the Yi’s are independent. Similarly, let Xn and Zn denote the collection of all
biomarker profiles Xi and treatment indices Zi, respectively. Let θt,m be the response
rate of patients in subgroup m under treatment t and let θ denote the collection of
all θt,m. We will use Γ(x) to denote the Gamma function evaluated at x.
C.1 Likelihood
Since the response for all patients is binary, the likelihood is extremely simple:







C.2 Prior for θt,m
The conjugate prior for θt,m is a Beta distribution with shape parameters a, b:
p(θt,m | Π) = beta(θt,m; a, b). (C.2)
C.3 Posterior for θt,m
The posterior distribution for θt,m is also a Beta distribution.
p(θt,m | Yn,Xn,Zn,Π) ∝ p(Yn | Xn,Zn,θ,Π) p(θ | Π)
∝ θnmt1t,m (1− θt,m)
nmt0 · beta(θt,m; a, b)
∝ θnmt1t,m (1− θt,m)
nmt0 · θa−1t,m (1− θt,m)
b−1
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∝ θnmt1+a−1t,m (1− θt,m)
nmt0+b−1
∝ beta(nmt1 + a, nmt0 + b)
C.4 Posterior for Π
We now report the posterior for the partition Π. There is a nice, closed form expres-
sion that we find.
p(Π | Yn,Xn,Zn) = p(Π)
∫




























































Γ(nmt1 + a) Γ(nmt0 + b)
Γ(a+ b+ nmt1 + nmt0)
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Appendix D Categorical Response Model
In this section, we report the details of the model for patients with a categorical
response.
We begin with some notation. Let n denote the total number of patients. Let
there be C possible outcomes. Let nmt denote the number of patients in subgroup m
receiving treatment t. Let nmtc be the number of patients in subgroup m receiving
treatment t with response c. Let Yn, Xn, and Zn denote the collection of all patient
responses Yi, biomarker profiles Xi, and treatment indices Zi, respectively. Note that
the Yi’s are independent. Let θc,t,m be the response rate of patients in subgroup m
under treatment t with outcome c and let θ denote the collection of all θc,t,m. We will
use Γ(x) to denote the Gamma function evaluated at x.
D.1 Likelihood
Since the response for all patients is categorical, the likelihood is extremely simple:








D.2 Prior for θc,t,m
The conjugate prior for θc,t,m is a Dirichlet distribution with parameter a = (a1, · · · , aC),
where ac > 0 for c ∈ {1, · · · , C}. We notate this by Dir(C, a).
D.3 Posterior for θc,t,m
The posterior distribution for θc,t,m is also a Dirichlet distribution: let κ = (nmt1, · · · , nmtC).
Then the posterior for θc,t,m = (θ1,t,m, · · · , θC,t,m) is θc,t,m ∼ Dir(C, a+κ). The deriva-
tion of this fact is found in a similar manner to the derivation done to find the posterior
of θt,m for a binary response in Appendix C.
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D.4 Posterior for Π
We now report the posterior for the partition Π.
p(Π | Yn,Xn,Zn) = p(Π) ·
∫









where the integration is over the simplex of non-negative θc,t,m summing to 1. Then,
we may write this as


















where there areM subgroups withm ∈ {1, . . . ,M}, T treatments with t ∈ {1, . . . , T},








This expression simplifies to



















which we may write as


















Note that this expression simplifies to the binary case when C = 2.
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Appendix E Normal Response Model
In this section, we report the details of the model for patients with a continuous,
normal response.
We begin with some notation. Let n denote the total number of patients. Let nmt
denote the number of patients in subgroup m receiving treatment t. Let Yi;t,m denote
the ith patient’s response out of the subset of patients that belong to subgroup m
and receive treatment t. Note that the Yi’s are independent. Let θt,m be the average
response of patients in subgroup m under treatment t. We will use N (a, b) to denote
a Gaussian distribution with mean a and variance b, and IG(a, b) to denote an inverse
Gamma distribution with mean b/a. Moreover, a subscript 0 on a parameter indicates
that said parameter is a hyperparameter. Let Yn and θ denote the collection of all
Yi;t,m and θt,m, respectively.
We have that,
Yi;t,m = θt,m + ϵi, (E.1)
where ϵi ∼ N (0, σ
2). Furthermore,
p(Yi;t,m | θt,m, σ






We compute and simplify the likelihood below:










p(Yi;t,m | θt,m, σ
2)

























(Yi;t,m − Y i;t,m + Y i;t,m − θt,m)
2}
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[(Yi;t,m − Y i;t,m)− (θt,m − Y i;t,m)]
2}





[(Yi;t,m − Y i;t,m)
2 + (θt,m − Y i;t,m)
2]}






[(Yi;t,m − Y i;t,m)
2] + n(θt,m − Y i;t,m)
2)}









n(θt,m − Y i;t,m)
2}









n(θt,m − Y i;t,m)
2}












n(θt,m − Y i;t,m)
2}











(Yi;t,m − Y i;t,m)
2
n− 1






n(θt,m − Y i;t,m)
2}
where SS = s2(n− 1)











(Yi;t,m − Y i;t,m)
2.
E.2 Priors
We have that the conjugate prior
p(θt,m, σ
2) = p(θt,m | σ
2) p(σ2).
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We now specify p(θt,m | σ
2) and p(σ2) where
p(θt,m | σ





































































Packaging the above expressions together, we may write the joint model as:
p(Yn,θ, σ
2,Π) ∝ p(Yn | θ, σ
2,Π) p(θ | Π) p(σ2) p(Π | c) p(c),
where p(c) = p(k) p(k1) p(k2) p(ck) p(ck1) p(ck2).
E.4 Posterior for θt,m
The posterior for θt,m is as follows:
p(θt,m | Yn, σ













































Yi + κ0θ0)θt,m + (
∑






[aθ2t,m + 2bθt,m + c]}
where a = n+ κ0; b =
∑
Yi + κ0θ0; c =
∑







































































θt,m | Yn, σ














E.5 Posterior for σ2
The posterior for σ2 is computed as follows:












































































E.6 Posterior for Π
We may now report the posterior for the partition Π:
p(Π | Yn, σ








































2 + κ0(θt,m − θ0)
2]}dθt,m






















t,m − 2κ0θ0θt,m + κ0θ
2
0]}dθt,m

















Yi;t,m + κ0θ0)θt,m + (
∑
i,t,m
(Y 2i;t,m) + κ0θ
2
0)]}dθt,m











[aθ2t,m + 2bθt,m + c]}dθt,m
where a = nmt + κ0; b =
∑
i,t,m
Yi;t,m + κ0θ0; c =
∑
i,t,m
(Y 2i;t,m) + κ0θ
2
0











































































































































































































































































Appendix F Regression Model
In this section, we describe the details for the Regression model. We begin with
some notation. Let nmt denote the number of patients in subgroup m receiving
treatment t. Let Xi, where i = 1 . . . nmt, denote the set of biomarker readings for
patient i in subgroup m receiving treatment t and Yi be the corresponding response
for that particular patient. Let Yn denote the collection of all patient responses, all
of whom are independent of one another. Similarly, let Xn denote the collection of
all biomarker profiles. Let βt,m be the linear regression coefficient vector for patients
in subgroup m with treatment t and let β be the collection of all βt,m. We say that
NB represents the number of biomarkers, and that N (a, b) represents the Gaussian
distribution with mean a and variance b. Additionally, IG(a, b) will represent the




i βt,m + ϵi, (F.1)


















From the computations above, the likelihood is:


































where Yt,m = {Yi}i∈Sm,zi=t, the vector of all the patient responses for patients in
subgroup m receiving treatment t and Xt,m = {Xi}i∈Sm,zi=t, the matrix of patient
biomarker values for patients in subgroup m receiving treatment t.
F.2 Priors
We now specify the priors p(βt,m) and p(σ
2) where p(βt,m) takes a multivariate normal
form and p(σ2) an inverse gamma form. We have that








T Σ−10 (βt,m − µ0)}, (F.3)
and that







We use variables with a subscript 0 to indicate hyperparameters.
F.3 Joint Model
Packaging the likelihood and priors together, it follows that the joint model is:
p(Yn,β, σ
2,Π|Xn) ∝ p(Yn | Xn,β, σ
2,Π) p(β|Π) p(σ2) p(Π|c) p(c),
































































In the above, p(c) = p(k) p(k1) p(k2) p(ck) p(ck1) p(ck2). More details on the exact




T (σ2 I)−1 (Yt,m −X
T
t,m βt,m) + (βt,m − µ0)
T Σ−10 (βt,m − µ0)
= YTt,m (σ
2 I)−1 Yt,m −Y
T
t,m (σ





















= βTt,m (Xt,m (σ
2 I)−1 XTt,m + Σ
−1
0 )βt,m − (Y
T
t,m(σ
















Now complete the square by adding and subtracting µTn Σ
−1
n µn.
= βTt,m (Xt,m (σ
2 I)−1 XTt,m + Σ
−1
0 )βt,m − (Y
T
t,m(σ






2 I)−1 Yt,m + Σ
−1















= (βt,m − µn)
T Σ−1n (βt,m − µn) +Y
T
t,m (σ










µn = (Xt,m (σ









Σn = (Xt,m (σ




Therefore, we can write our joint model in the following way:
p(Yn,β, σ
2,Π|Xn) ∝ p(Yn | Xn,β, σ






























F.4 Posterior for βt,m





T Σ−1n (βt,m − µn)}
∝ N (µn,Σn),
where N (µn,Σn) denotes a multivariate normal pdf with mean vector µn and covari-
ance matrix Σn.
F.5 Posterior for σ2
We may now write the posterior for σ2:
p(σ2|Yn,Xn)































































and IG(an, bn) denotes an inverse-gamma pdf with mean an and variance bn.
F.6 Posterior for Π

























































































































































In this section, we describe a Metropolis-Hasting algorithm to update the partition
in each iteration. The algorithm has three steps, which we will describe in what
follows. As a reminder, we use the letter k to denote the index of the biomarker for
the first split, and k1 and k2 denote the indices of the biomarkers for the second splits.
The variables csk, c
s
k1
, and csk2 denote the locations of the splits. The superscript s
represents the sth iteration; we will drop the superscript when it is clear from context
what we mean.
G.1 Step 1: Keep k, k1, k2 fixed, update ck, ck1, ck2
In the first step, we fix the biomarkers to split on, and update the locations of the
splits. Denote which biomarkers are split upon in the current partition and the







, csk2) in iteration s. We







, c∗k2) as follows.
G.1.1 Discrete Biomarkers
When the biomarkers are not all continuous, we use the prior densities as proposals.
G.1.2 Continuous Biomarkers









We take csk, c
s
k1





, and ηsk2 respectively to occupy
the real line. Then, we generate η∗k, η
∗
k1




, and ηsk2 respectively and variance σ




we must transform back to the original ranges that csk, c
s
k1
, and csk2 were in. Thus, we
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Table 2: The continuous biomarker MCMC sampling transformations.





k ∼ N (η
s
k, σ
2) → c∗k. (G.1)
With a new c∗, we have a new partition Π. We summarize all the transformations in
Table 2.
G.1.3 Posterior Ratio
Recall that the joint hierarchical model is
p(Yn,Θ,Π | Xn,Zn) ∝ p(Yn | Xn,Zn,Θ,Π) p(Θ | Π) p(Π | c)p(c).
Thus, in a similar manner, we may write
p(Yn,Θ,Π
∗ | Xn,Zn) ∝ p(Yn | Xn,Zn,Θ,Π
∗) p(Θ | Π∗) p(Π∗ | c∗)p(c∗)
Then, the MCMC posterior ratio is:
p(Yn | Xn,Zn,Θ,Π
∗) p(Θ | Π∗) p(Π∗ | c∗)p(c∗)




Let us now consider the MCMC proposal ratio. In the discrete case, it is the ratio of






















(1 + c∗k)(1− c
∗
k)
(1 + ck)(1− ck)
=
(1 + c∗k)(1− c
∗
k)
(1 + ck)(1− ck)
.



























(1 + ck1)(1− ck1)
=




(1 + ck1)(1− ck1)
.



























(1 + ck2)(1− ck2)
=




(1 + ck2)(1− ck2)
.


































































The acceptance ratio is the product of the posterior ratio and the proposal ratio. Let
r be the acceptance ratio. Then,
r =
p(Yn | Xn,Zn,Θ,Π
∗) p(Θ | Π∗) p(Π∗ | c∗) p(c∗)





Note that p(Π | c) = 1 since if we know which biomarkers we split on and where






p(Θ | Π∗) p(k∗) p(k∗1 | k


































since k, k1, k2 are fixed. Then, we have that
r =
p(Yn | Xn,Zn,Θ,Π
∗) p(Θ | Π∗) p(c∗k) p(c
∗
k1















, c∗k2) with probability min(r, 1). If c
∗ is
rejected, we instead store c = (k, k1, k2, ck, ck1 , ck2).
G.2 Step 2: Update k, k1, k2, ck, ck1, ck2
In this step, we update both the biomarker indices and the location of the splits.
G.2.1 New Biomarker indices
We uniformly sample new k∗, k∗1, k
∗
2 values from the set of all biomarkers. We then
propose a new set of biomarkers and split locations as c∗ = (k
∗, k∗1, k
∗
2, ck∗ , ck∗1 , ck∗2 )
using the priors (all of which are uniform) over the support of the relevant biomarkers.
G.2.2 Posterior Ratio
The posterior ratio in Step 2 is found exactly the same way as in Step 1.
G.2.3 Proposal Ratio
Let the proposal ratio in Step 2 be the ratio of the prior on our partition Π denoted
p(Π) to the prior on our partition Π∗ denoted p(Π∗). This simplification occurs
because all values are drawn uniformly from the priors.
G.2.4 Acceptance Ratio
Let r be the acceptance ratio. Then,
r =
p(Yn | Xn,Zn,Θ,Π
∗) p(Θ | Π∗) p(Π∗)









∗) p(Θ | Π∗) p(Π∗)







∗) p(Θ | Π∗)
p(Yn | Xn,Zn,Θ,Π) p(Θ | Π)
.
G.2.5 Storing Values
We accept c∗ = (k
∗, k∗1, k
∗
2, ck∗ , ck∗1 , ck∗2 ) with probability min(r, 1). Otherwise, we keep
the values stored in Step 1.
G.3 Step 3: Update model parameters
In this final step, we update the posterior Θ parameters for each sampling model.
The details of this are found in Section 2.2.
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Number of Patients: 60
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.961 0.697 0.612 0.889 0.588 0.464 0.65 0.457 0.047
TNR 0.896 0.846 0.973 0.904 0.901 0.996 0.938 0.944 1
SFE 0 0.018 0 0 0.008 0 0 0.002 0
SUB 3.506 3.221 2.934 3.465 3.378 3.895 3.491 3.518 3.755
ALL 1.88 1.803 1.923 1.777 1.81 1.419 1.807 1.762 1.715
Scenario 1 LRV
Number of Patients: 70
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.985 0.71 0.654 0.965 0.6 0.558 0.802 0.468 0.265
TNR 0.903 0.855 0.91 0.905 0.908 0.949 0.925 0.949 0.999
SFE 0.002 0.012 0 0 0.004 0 0 0.001 0
SUB 3.485 3.154 3.543 3.453 3.28 3.581 3.484 3.537 3.622
ALL 1.837 1.731 2.5 1.776 1.824 1.96 1.811 1.846 2.111
Scenario 1 LRV
Number of Patients: 80
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.982 0.715 0.785 0.981 0.604 0.316 0.832 0.471 0.048
TNR 0.92 0.86 0.997 0.924 0.913 1 0.943 0.953 1
SFE 0 0.011 0 0 0.004 0 0 0.001 0
SUB 3.449 3.13 3.303 3.503 3.333 3.368 3.545 3.457 3.55
ALL 1.779 1.813 1.835 1.809 1.782 1.578 1.82 1.857 1.405
Scenario 1 LRV
Number of Patients: 90
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.994 0.705 0.936 0.993 0.588 0.923 0.883 0.447 0.875
TNR 0.929 0.871 0.891 0.929 0.923 0.948 0.942 0.961 0.954
SFE 0 0.008 0.001 0 0.002 0 0 0 0
SUB 3.472 3.176 3.607 3.535 3.378 3.774 3.49 3.545 3.736
ALL 1.74 1.76 0.96 1.83 1.826 1.861 1.785 1.848 1.962
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Scenario 1 LRV
Number of Patients: 100
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.995 0.717 0.98 0.984 0.598 0.808 0.849 0.454 0.169
TNR 0.939 0.867 1 0.939 0.925 1 0.949 0.967 1
SFE 0.001 0.004 0 0 0.001 0 0 0 0
SUB 3.512 3.074 4.096 3.566 3.301 3.669 3.557 3.478 4.337
ALL 1.881 1.831 1.289 1.812 1.82 2.293 1.826 1.82 2.448
Scenario 1 LRV
Number of Patients: 110
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.999 0.724 0.962 0.989 0.608 0.923 0.958 0.464 0.836
TNR 0.934 0.878 1 0.934 0.933 1 0.938 0.971 1
SFE 0 0.003 0 0 0.001 0 0 0 0
SUB 3.42 3.097 4.188 3.567 3.281 3.657 3.473 3.483 2.766
ALL 1.841 1.653 1.522 1.873 1.762 2.227 1.833 1.775 1.267
Scenario 1 LRV
Number of Patients: 120
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.998 0.726 1 0.998 0.609 1 0.928 0.467 1
TNR 0.935 0.868 0.943 0.935 0.922 0.952 0.943 0.961 0.978
SFE 0 0.005 0 0 0.001 0 0 0 0
SUB 3.466 3.154 3.875 3.46 3.261 4.976 3.453 3.456 3.847
ALL 1.858 1.679 1.366 1.886 1.823 1.968 1.907 1.738 1.548
Scenario 1 LRV
Number of Patients: 130
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.999 0.74 0.99 0.999 0.627 0.961 0.979 0.486 0.907
TNR 0.929 0.869 0.958 0.929 0.926 0.983 0.933 0.966 0.999
SFE 0 0.004 0 0 0.002 0 0 0 0
SUB 3.442 3.086 3.255 3.315 3.109 3.891 3.271 3.266 3.685
ALL 1.926 1.765 2.813 1.811 1.788 1.891 1.735 1.752 4.516
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Scenario 1 LRV
Number of Patients: 140
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.999 0.733 1 0.999 0.614 1 0.979 0.468 1
TNR 0.937 0.884 0.889 0.937 0.94 0.949 0.937 0.976 0.996
SFE 0 0.002 0 0 0 0 0 0 0
SUB
ALL
Table 3: Scenario 1, δ = 0.5
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Scenario 1 LRV
Number of Patients: 60
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.945 0.564 0.518 0.863 0.445 0.245 0.602 0.318 0
TNR 0.925 0.918 0.989 0.936 0.952 1 0.966 0.974 1
SFE 0 0.006 0 0 0.002 0 0 0 0
SUB 3.625 3.404 3.424 3.629 3.552 3.746 3.651 3.676 3.739
ALL 1.807 1.807 2.05 1.749 1.752 1.332 1.776 1.895 2.091
Scenario 1 LRV
Number of Patients: 70
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.977 0.588 0.573 0.948 0.469 0.435 0.73 0.339 0.018
TNR 0.939 0.922 0.938 0.939 0.955 0.983 0.956 0.978 1
SFE 0.001 0.003 0 0 0.001 0 0 0 0
SUB 3.646 3.292 3.778 3.613 3.507 3.583 3.633 3.617 3.581
ALL 1.8 1.841 1.799 1.768 1.833 2.392 1.806 1.839 2.247
Scenario 1 LRV
Number of Patients: 80
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.973 0.602 0.512 0.953 0.482 0.118 0.81 0.349 0.015
TNR 0.949 0.921 1 0.953 0.955 1 0.965 0.979 1
SFE 0 0.003 0 0 0.001 0 0 0 0
SUB 3.588 3.291 3.664 3.607 3.444 2.993 3.604 3.597 3.24
ALL 1.755 1.808 1.793 1.791 1.781 1.15 1.771 1.917 1.185
Scenario 1 LRV
Number of Patients: 90
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.983 0.593 0.926 0.983 0.466 0.889 0.835 0.326 0.843
TNR 0.957 0.93 0.948 0.958 0.962 0.953 0.968 0.983 0.957
SFE 0 0.002 0 0 0 0 0 0 0
SUB 3.591 3.393 3.453 3.618 3.529 4.135 3.632 3.676 3.391
ALL 1.855 1.793 1.523 1.742 1.777 1.72 1.768 1.783 1.696
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Scenario 1 LRV
Number of Patients: 100
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.986 0.611 0.915 0.975 0.481 0.568 0.832 0.336 0.016
TNR 0.961 0.929 1 0.962 0.966 1 0.97 0.987 1
SFE 0 0.001 0 0 0 0 0 0 0
SUB 3.628 3.222 4.019 3.597 3.473 4.374 3.616 3.604 3.712
ALL 1.854 1.868 2.074 1.845 1.801 1.418 1.851 1.863 1.532
Scenario 1 LRV
Number of Patients: 110
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.991 0.625 0.929 0.981 0.496 0.878 0.941 0.351 0.64
TNR 0.961 0.935 1 0.961 0.969 1 0.966 0.988 1
SFE 0 0.001 0 0 0 0 0 0 0
SUB 3.51 3.397 3.348 3.541 3.458 3.186 3.607 3.603 3.408
ALL 1.699 1.884 2.194 1.814 1.78 0.663 1.776 1.682 2.059
Scenario 1 LRV
Number of Patients: 120
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.994 0.631 1 0.994 0.504 1 0.894 0.36 0.977
TNR 0.965 0.921 0.95 0.965 0.957 0.967 0.971 0.981 1
SFE 0 0.001 0 0 0 0 0 0 0
SUB 3.432 3.246 2.874 3.605 3.396 3.339 3.615 3.593 4.671
ALL 1.809 1.852 1.215 1.743 1.846 1.522 1.827 1.835 2.102
Scenario 1 LRV
Number of Patients: 130
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.995 0.656 0.964 0.995 0.53 0.922 0.955 0.385 0.864
TNR 0.96 0.923 0.982 0.96 0.961 0.998 0.961 0.984 1
SFE 0 0.002 0 0 0.001 0 0 0 0
SUB 3.692 3.396 1.792 3.613 3.418 3.761 3.508 3.391 4.315
ALL 2.032 1.84 3.848 1.94 1.724 1.57 1.711 1.72 2.385
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Scenario 1 LRV
Number of Patients: 140
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.995 0.646 1 0.995 0.515 1 0.975 0.366 0.993
TNR 0.964 0.936 0.942 0.964 0.971 0.99 0.964 0.99 1
SFE 0 0.001 0 0 0 0 0 0 0
SUB
ALL
Table 4: Scenario 1, δ = 0.7
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Scenario 1 LRV
Number of Patients: 60
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.856 0.348 0.266 0.779 0.244 0.001 0.501 0.151 0
TNR 0.963 0.973 1 0.971 0.985 1 0.986 0.993 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.75 3.564 3.348 3.736 3.7 3.584 3.753 3.741 3.903
ALL 1.794 1.81 1.494 1.798 1.846 1.799 1.848 1.868 2.234
Scenario 1 LRV
Number of Patients: 70
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.954 0.388 0.356 0.905 0.278 0.076 0.635 0.174 0
TNR 0.971 0.976 0.992 0.972 0.988 1 0.983 0.996 1
SFE 0.001 0 0 0 0 0 0 0 0
SUB 3.651 3.586 4.008 3.692 3.654 3.769 3.669 3.682 3.61
ALL 1.74 1.792 2.742 1.804 1.773 2.443 1.775 1.814 1.564
Scenario 1 LRV
Number of Patients: 80
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.953 0.416 0.142 0.914 0.3 0.019 0.752 0.189 0
TNR 0.978 0.974 1 0.979 0.988 1 0.987 0.996 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.704 3.478 3.399 3.65 3.567 3.25 3.738 3.662 3.76
ALL 1.817 1.823 2.452 1.88 1.821 1.369 1.803 1.842 2.112
Scenario 1 LRV
Number of Patients: 90
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.966 0.407 0.879 0.956 0.284 0.845 0.717 0.169 0.802
TNR 0.986 0.976 0.953 0.986 0.988 0.958 0.991 0.996 0.979
SFE 0 0 0 0 0 0 0 0 0
SUB 3.724 3.649 4.18 3.743 3.713 3.659 3.745 3.755 3.451
ALL 1.719 1.683 1.841 1.835 1.77 1.406 1.734 1.806 2.718
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Scenario 1 LRV
Number of Patients: 100
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.974 0.432 0.614 0.939 0.303 0.029 0.774 0.18 0
TNR 0.987 0.98 1 0.987 0.992 1 0.993 0.998 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.741 3.625 3.749 3.724 3.595 3.935 3.73 3.692
ALL 1.772 1.905 1.157 1.746 1.867 1.882 1.766 1.767 1.696
Scenario 1 LRV
Number of Patients: 110
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.98 0.455 0.859 0.972 0.325 0.709 0.902 0.198 0.185
TNR 0.982 0.98 1 0.983 0.992 1 0.984 0.998 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.712 3.571 2.956 3.656 3.583 3.093 3.682 3.729 3.758
ALL 1.882 1.849 1.308 1.756 1.793 0.827 1.834 1.767 2.492
Scenario 1 LRV
Number of Patients: 120
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.981 0.473 1 0.973 0.343 0.98 0.845 0.214 0.842
TNR 0.987 0.969 0.972 0.988 0.986 1 0.991 0.994 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.673 3.514 4.276 3.684 3.666 4.546 3.746 3.638
ALL 1.792 1.863 1.933 1.668 2.041 1.39 1.705 1.79 1.249
Scenario 1 LRV
Number of Patients: 130
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.986 0.509 0.908 0.986 0.378 0.864 0.937 0.245 0.781
TNR 0.985 0.971 0.999 0.985 0.987 1 0.985 0.995 1
SFE 0 0.001 0 0 0 0 0 0 0
SUB 3.716 3.559 3.83 3.689 3.631 3.659 3.588 3.651
ALL 1.76 1.771 3.954 1.88 1.834 1.736 1.728 1.833 2.313
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Scenario 1 LRV
Number of Patients: 140
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.989 0.496 1 0.989 0.36 0.995 0.96 0.225 0.94
TNR 0.989 0.979 0.993 0.989 0.993 1 0.989 0.998 1









Number of Patients: 60
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.958 0.779 1 0.957 0.686 0.984 0.801 0.569 0.843
TNR 0.991 0.925 0.949 0.992 0.964 0.992 0.997 0.985 1
SFE 0 0.01 0 0 0.003 0 0 0 0
SUB 3.738 3.729 3.629 3.745 3.76 3.913 3.778 3.744 3.243
ALL 2.708 2.742 3.079 2.693 2.82 2.529 2.72 2.724 2.737
Scenario 2 LRV
Number of Patients: 70
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.96 0.793 0.978 0.959 0.699 0.921 0.854 0.578 0.738
TNR 0.986 0.928 1 0.987 0.969 1 0.987 0.992 1
SFE 0 0.004 0 0 0.001 0 0 0 0
SUB 3.693 3.672 3.457 3.756 3.718 4.226 3.742 3.757 4.082
ALL 2.749 2.76 2.899 2.805 2.768 3.183 2.699 2.785 3.302
Scenario 2 LRV
Number of Patients: 80
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.956 0.782 0.941 0.956 0.687 0.896 0.9 0.568 0.618
TNR 0.995 0.941 0.979 0.995 0.975 0.991 0.995 0.991 0.998
SFE 0 0.006 0 0 0.002 0 0 0 0
SUB 3.767 3.742 3.335 3.763 3.696 4.337 3.787 3.765 3.909
ALL 2.73 2.733 2.657 2.8 2.842 3.125 2.747 2.762 3.047
Scenario 2 LRV
Number of Patients: 90
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.955 0.785 0.934 0.955 0.691 0.933 0.954 0.576 0.933
TNR 0.998 0.96 1 0.998 0.982 1 0.998 0.993 1
SFE 0 0.002 0 0 0 0 0 0 0
SUB 3.76 3.696 3.659 3.732 3.73 3.918 3.752 3.774 3.719
ALL 2.719 2.697 2.671 2.718 2.75 2.216 2.734 2.822 2.866
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Scenario 2 LRV
Number of Patients: 100
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.955 0.792 0.933 0.955 0.696 0.933 0.955 0.58 0.899
TNR 0.995 0.973 1 0.995 0.992 1 0.995 0.998 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.781 3.744 3.62 3.727 3.754 3.638 3.756 3.811 4.313
ALL 2.728 2.725 1.902 2.829 2.766 2.538 2.755 2.784 2.837
Scenario 2 LRV
Number of Patients: 110
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.952 0.798 0.933 0.952 0.701 0.933 0.952 0.584 0.918
TNR 1 0.976 1 1 0.992 1 1 0.998 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.84 3.686 3.124 3.757 3.745 3.945 3.695 3.727 4.462
ALL 2.744 2.77 1.968 2.764 2.773 3.536 2.774 2.818 2.542
Scenario 2 LRV
Number of Patients: 120
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.957 0.798 0.933 0.957 0.7 0.933 0.938 0.581 0.933
TNR 1 0.976 1 1 0.993 1 1 0.998 1
SFE 0 0.001 0 0 0 0 0 0 0
SUB 3.762 3.607 3.583 3.693 3.663 3.557 3.771 3.787 3.997
ALL 2.776 2.605 2.475 2.795 2.831 1.583 2.791 2.736 3.102
Scenario 2 LRV
Number of Patients: 130
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.956 0.81 0.934 0.956 0.71 0.933 0.946 0.589 0.907
TNR 0.998 0.975 1 0.998 0.994 1 0.998 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.783 3.793 5.313 3.736 3.708 3.45 3.659 3.715 2.868
ALL 2.78 2.57 2.35 2.838 2.792 3.763 2.817 2.661 1.782
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Scenario 2 LRV
Number of Patients: 140
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.954 0.8 0.933 0.954 0.701 0.933 0.954 0.582 0.933
TNR 1 0.985 1 1 0.998 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB
ALL
Table 6: Scenario 2, δ = 0.5
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Scenario 2 LRV
Number of Patients: 60
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.932 0.674 0.996 0.92 0.57 0.949 0.762 0.447 0.743
TNR 0.997 0.972 0.988 0.998 0.987 1 0.998 0.995 1
SFE 0 0.003 0 0 0 0 0 0 0
SUB 3.767 3.782 3.559 3.758 3.761 3.613 3.798 3.737 4.028
ALL 2.668 2.733 2.978 2.783 2.782 2.401 2.781 2.791 2.958
Scenario 2 LRV
Number of Patients: 70
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.928 0.696 0.931 0.927 0.59 0.827 0.824 0.46 0.52
TNR 0.997 0.976 1 0.997 0.993 1 0.997 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.765 3.758 4 3.763 3.762 3.828 3.738 3.718 3.63
ALL 2.751 2.805 2.863 2.783 2.745 2.442 2.763 2.743 3.164
Scenario 2 LRV
Number of Patients: 80
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.94 0.694 0.928 0.94 0.591 0.81 0.872 0.467 0.465
TNR 0.997 0.977 0.994 0.997 0.991 1 0.997 0.997 1
SFE 0 0.002 0 0 0 0 0 0 0
SUB 3.723 3.732 3.702 3.733 3.708 4.038 3.749 3.733 3.866
ALL 2.716 2.775 2.635 2.817 2.853 2.635 2.782 2.678 2.531
Scenario 2 LRV
Number of Patients: 90
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.935 0.703 0.933 0.935 0.603 0.933 0.917 0.484 0.923
TNR 0.998 0.983 1 0.998 0.993 1 0.998 0.998 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.732 3.772 3.546 3.74 3.73 4.178 3.768 3.771 3.713
ALL 2.772 2.663 3.011 2.721 2.737 2.055 2.757 2.745 2.934
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Scenario 2 LRV
Number of Patients: 100
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.934 0.714 0.933 0.934 0.613 0.93 0.934 0.492 0.829
TNR 0.998 0.992 1 0.998 0.998 1 0.998 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.737 3.765 3.746 3.709 3.714 3.039 3.71 3.796 3.678
ALL 2.709 2.632 3.461 2.853 2.709 2.83 2.777 2.716 4.246
Scenario 2 LRV
Number of Patients: 110
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.935 0.722 0.933 0.935 0.62 0.933 0.925 0.5 0.845
TNR 1 0.992 1 1 0.998 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.749 3.742 3.862 3.688 3.737 3.714 3.715 3.783 3.82
ALL 2.706 2.697 2.601 2.711 2.762 2.443 2.793 2.662 2.519
Scenario 2 LRV
Number of Patients: 120
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.937 0.724 0.933 0.936 0.621 0.933 0.917 0.5 0.933
TNR 1 0.992 1 1 0.998 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.735 3.763 3.413 3.818 3.715 4.082 3.739 3.68 4.011
ALL 2.665 2.735 2.211 2.685 2.761 3.09 2.761 2.653 2.913
Scenario 2 LRV
Number of Patients: 130
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.94 0.74 0.933 0.94 0.635 0.926 0.93 0.511 0.876
TNR 1 0.993 1 1 0.998 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.758 3.772 3.708 3.655 3.815 3.597 3.689 3.708 5.138
ALL 2.9 2.761 2.544 2.66 2.668 2.208 2.793 2.927 1.894
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Scenario 2 LRV
Number of Patients: 140
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.94 0.732 0.933 0.94 0.629 0.933 0.94 0.507 0.933
TNR 1 0.997 1 1 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB
ALL
Table 7: Scenario 2, δ = 0.7
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Scenario 2 LRV
Number of Patients: 60
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.882 0.497 0.966 0.85 0.387 0.834 0.654 0.268 0.578
TNR 1 0.995 1 1 0.999 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.745 3.728 3.336 3.755 3.759 3.605 3.766 3.754 3.413
ALL 2.754 2.762 2.212 2.682 2.814 2.734 2.713 2.838 2.783
Scenario 2 LRV
Number of Patients: 70
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.882 0.53 0.814 0.865 0.413 0.585 0.748 0.284 0.195
TNR 1 0.998 1 1 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.771 3.747 3.768 3.741 3.742 3.746 3.785 3.77 3.601
ALL 2.722 2.793 2.806 2.73 2.691 2.013 2.745 2.781 3.432
Scenario 2 LRV
Number of Patients: 80
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.907 0.548 0.857 0.907 0.437 0.612 0.809 0.311 0.278
TNR 0.998 0.995 1 0.998 0.998 1 0.998 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.768 3.802 3.572 3.781 3.748 3.705 3.747 3.72 3.357
ALL 2.823 2.822 2.581 2.682 2.753 1.972 2.751 2.763 2.731
Scenario 2 LRV
Number of Patients: 90
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.897 0.572 0.933 0.897 0.465 0.928 0.87 0.342 0.858
TNR 1 0.996 1 1 0.999 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.792 3.718 3.191 3.756 3.707 3.754 3.729 3.76 3.702
ALL 2.762 2.749 2.469 2.73 2.78 2.714 2.784 2.785 2.994
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Scenario 2 LRV
Number of Patients: 100
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.902 0.589 0.931 0.902 0.481 0.89 0.893 0.355 0.666
TNR 1 0.999 1 1 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.723 3.76 4.286 3.777 3.734 3.495 3.83 3.721 3.932
ALL 2.719 2.694 2.857 2.746 2.709 2.883 2.681 2.745 2.753
Scenario 2 LRV
Number of Patients: 110
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.911 0.603 0.933 0.911 0.495 0.921 0.893 0.367 0.575
TNR 1 0.999 1 1 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.795 3.806 4.137 3.706 3.704 3.731 3.662 3.768 3.986
ALL 2.746 2.776 2.11 2.823 2.741 1.671 2.727 2.742 1.255
Scenario 2 LRV
Number of Patients: 120
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.913 0.608 0.933 0.913 0.5 0.933 0.894 0.374 0.932
TNR 1 0.999 1 1 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.71 3.666 3.635 3.767 3.802 3.378 3.764 3.727 3.821
ALL 2.783 2.716 2.951 2.721 2.758 2.562 2.674 2.67 3.094
Scenario 2 LRV
Number of Patients: 130
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.915 0.63 0.932 0.915 0.52 0.906 0.906 0.389 0.778
TNR 1 0.999 1 1 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.799 3.732 4.021 3.757 3.772 4.385 3.828 3.741 3.443
ALL 2.914 2.647 3.573 2.852 2.723 1.043 2.71 2.595 1.892
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Scenario 2 LRV
Number of Patients: 140
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.917 0.626 0.933 0.917 0.519 0.933 0.917 0.392 0.926
TNR 1 1 1 1 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB
ALL





Number of Patients: 60
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.848 0.774 0.846 0.784 0.677 0.725 0.522 0.549 0.514
TNR 0.672 0.827 0.977 0.707 0.91 1 0.857 0.965 1
SFE 0 0.012 0 0 0.004 0 0 0.001 0
SUB 3.737 3.628 3.964 3.728 3.692 3.755 3.728 3.757 4.011
ALL 3.01 2.94 3.306 2.898 2.939 2.971 2.931 2.956 3.1
Scenario 3 LRV
Number of Patients: 70
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.865 0.791 0.854 0.785 0.692 0.674 0.591 0.556 0.41
TNR 0.694 0.817 1 0.728 0.902 1 0.834 0.959 1
SFE 0 0.007 0 0 0.001 0 0 0 0
SUB 3.73 3.66 3.661 3.714 3.733 3.848 3.788 3.729 3.713
ALL 2.92 2.979 2.912 2.902 2.977 2.965 2.906 2.901 3.683
Scenario 3 LRV
Number of Patients: 80
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.873 0.79 0.957 0.84 0.688 0.875 0.647 0.553 0.611
TNR 0.814 0.847 0.994 0.821 0.923 1 0.894 0.97 1
SFE 0 0.008 0 0 0.002 0 0 0.001 0
SUB 3.721 3.641 3.593 3.731 3.676 3.63 3.745 3.749 3.934
ALL 3.004 2.863 2.746 2.912 2.996 2.897 2.96 2.985 2.343
Scenario 3 LRV
Number of Patients: 90
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.921 0.805 0.98 0.883 0.698 0.947 0.748 0.555 0.814
TNR 0.873 0.874 0.998 0.877 0.946 1 0.922 0.984 1
SFE 0 0.001 0 0 0 0 0 0 0
SUB 3.748 3.596 3.555 3.686 3.688 3.543 3.707 3.75 3.915
ALL 2.965 2.972 3.654 2.932 3.022 2.616 2.995 2.979 3.097
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Scenario 3 LRV
Number of Patients: 100
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.912 0.802 0.978 0.882 0.698 0.964 0.783 0.561 0.907
TNR 0.939 0.894 1 0.94 0.958 1 0.95 0.988 1
SFE 0 0.001 0 0 0 0 0 0 0
SUB 3.765 3.635 3.625 3.665 3.717 3.605 3.651 3.805 3.784
ALL 2.905 2.992 3.005 2.965 2.974 3.461 2.918 2.983 3.448
Scenario 3 LRV
Number of Patients: 110
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.945 0.824 0.96 0.927 0.718 0.944 0.831 0.573 0.885
TNR 0.937 0.867 1 0.94 0.944 1 0.953 0.983 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.719 3.621 3.318 3.647 3.612 3.264 3.626 3.687 3.539
ALL 3.062 3.122 3.532 2.936 2.979 2.767 2.863 2.914 2.581
Scenario 3 LRV
Number of Patients: 120
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.942 0.807 0.988 0.927 0.701 0.96 0.835 0.559 0.922
TNR 0.972 0.897 0.975 0.973 0.96 0.998 0.979 0.989 1
SFE 0 0.002 0 0 0 0 0 0 0
SUB 3.594 3.615 3.895 3.596 3.696 4.859 3.604 3.713 3.733
ALL 3.004 3.061 2.356 2.883 2.976 2.882 2.988 2.942 2.785
Scenario 3 LRV
Number of Patients: 130
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.948 0.818 0.971 0.932 0.71 0.966 0.863 0.566 0.908
TNR 0.969 0.893 1 0.969 0.963 1 0.983 0.993 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.394 3.638 4.028 3.365 3.623 4.461 3.487 3.75 2.778
ALL 3.148 2.859 3.327 3.095 3.107 3.299 2.992 2.937 2.465
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Scenario 3 LRV
Number of Patients: 140
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.959 0.821 0.939 0.945 0.711 0.938 0.875 0.566 0.938
TNR 0.983 0.898 1 0.984 0.965 1 0.987 0.993 1
SFE 0 0 0 0 0 0 0 0 0
SUB
ALL
Table 9: Scenario 3, δ = 0.5
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Scenario 3 LRV
Number of Patients: 60
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.804 0.658 0.759 0.728 0.546 0.611 0.449 0.411 0.404
TNR 0.719 0.919 1 0.755 0.965 1 0.902 0.989 1
SFE 0 0.003 0 0 0.001 0 0 0 0
SUB 3.735 3.702 3.586 3.703 3.719 3.697 3.738 3.782 3.876
ALL 2.988 2.984 3.398 2.937 2.948 2.909 2.964 2.94 3.393
Scenario 3 LRV
Number of Patients: 70
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.828 0.677 0.683 0.739 0.56 0.505 0.541 0.419 0.222
TNR 0.736 0.907 1 0.764 0.956 1 0.861 0.985 1
SFE 0 0.001 0 0 0 0 0 0 0
SUB 3.666 3.628 3.849 3.74 3.754 4.139 3.691 3.772 3.544
ALL 2.987 2.984 2.661 3.046 2.961 3.856 2.937 3.008 2.987
Scenario 3 LRV
Number of Patients: 80
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.839 0.686 0.902 0.791 0.57 0.766 0.581 0.431 0.482
TNR 0.838 0.921 1 0.844 0.966 1 0.905 0.99 1
SFE 0 0.002 0 0 0.001 0 0 0 0
SUB 3.738 3.71 3.802 3.765 3.727 3.681 3.73 3.697 3.625
ALL 2.937 2.939 2.221 2.932 2.977 2.807 2.925 2.939 2.2
Scenario 3 LRV
Number of Patients: 90
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.891 0.702 0.961 0.846 0.58 0.902 0.692 0.436 0.683
TNR 0.896 0.94 1 0.896 0.979 1 0.937 0.995 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.715 3.655 3.524 3.724 3.729 3.846 3.724 3.746 3.685
ALL 2.99 3.008 3.01 3.011 2.89 2.237 2.974 2.914 3.058
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Scenario 3 LRV
Number of Patients: 100
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.884 0.707 0.967 0.843 0.591 0.938 0.719 0.451 0.791
TNR 0.958 0.951 1 0.958 0.983 1 0.964 0.996 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.658 3.701 3.679 3.718 3.72 3.759 3.697 3.702 3.856
ALL 2.942 2.993 3.032 2.948 2.994 2.506 2.859 3.009 2.49
Scenario 3 LRV
Number of Patients: 110
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.919 0.731 0.948 0.893 0.61 0.922 0.753 0.462 0.686
TNR 0.966 0.932 1 0.973 0.976 1 0.978 0.995 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.702 3.606 3.262 3.645 3.754 3.067 3.671 3.729 4.37
ALL 2.991 2.908 2.801 2.91 2.941 2.471 2.928 2.94 3.064
Scenario 3 LRV
Number of Patients: 120
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.921 0.72 0.964 0.895 0.601 0.939 0.784 0.457 0.861
TNR 0.981 0.948 0.996 0.981 0.983 1 0.984 0.996 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.557 3.725 3.989 3.607 3.702 4.419 3.513 3.738 3.031
ALL 2.922 3.025 3.342 3.046 2.95 4.192 2.9 2.868 1.854
Scenario 3 LRV
Number of Patients: 130
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.928 0.734 0.967 0.908 0.614 0.933 0.827 0.466 0.803
TNR 0.977 0.948 1 0.977 0.987 1 0.987 0.998 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.469 3.645 3.52 3.618 3.705 3.681 3.498 3.7 2.095
ALL 3.006 2.883 4.234 2.944 2.842 4.098 3.016 3.04 2.485
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Scenario 3 LRV
Number of Patients: 140
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.941 0.738 0.938 0.928 0.616 0.938 0.842 0.47 0.934
TNR 0.99 0.949 1 0.99 0.986 1 0.994 0.998 1
SFE 0 0 0 0 0 0 0 0 0
SUB
ALL
Table 10: Scenario 3, δ = 0.7
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Scenario 3 LRV
Number of Patients: 60
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.734 0.462 0.601 0.589 0.347 0.422 0.335 0.228 0.242
TNR 0.781 0.98 1 0.836 0.993 1 0.936 0.998 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.728 3.708 3.811 3.729 3.778 3.711 3.765 3.756 3.681
ALL 2.909 2.978 3.007 3.005 2.985 2.763 2.98 2.907 3.24
Scenario 3 LRV
Number of Patients: 70
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.744 0.484 0.482 0.654 0.363 0.275 0.435 0.239 0.05
TNR 0.791 0.972 1 0.808 0.99 1 0.894 0.998 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.746 3.754 4.101 3.7 3.669 3.635 3.705 3.782 3.514
ALL 2.975 3.005 3.285 2.972 3.012 2.889 2.945 2.968 3.128
Scenario 3 LRV
Number of Patients: 80
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.769 0.513 0.787 0.724 0.393 0.552 0.479 0.265 0.321
TNR 0.874 0.977 1 0.875 0.993 1 0.934 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.78 3.716 3.508 3.726 3.751 3.76 3.715 3.814 4.111
ALL 2.919 2.994 3.04 2.982 2.989 2.222 2.944 2.941 2.748
Scenario 3 LRV
Number of Patients: 90
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.832 0.532 0.904 0.79 0.408 0.761 0.62 0.278 0.465
TNR 0.906 0.985 1 0.906 0.996 1 0.954 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.709 3.707 3.8 3.718 3.765 3.805 3.716 3.787 3.207
ALL 3.003 2.862 3.417 2.927 3.023 3.13 2.941 2.978 3.356
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Scenario 3 LRV
Number of Patients: 100
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.838 0.551 0.928 0.787 0.432 0.84 0.635 0.302 0.519
TNR 0.971 0.987 1 0.971 0.996 1 0.973 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.747 3.733 3.553 3.692 3.738 4.195 3.683 3.823 4.086
ALL 3.025 2.927 2.776 2.924 2.946 2.426 2.957 2.949 3.277
Scenario 3 LRV
Number of Patients: 110
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.886 0.576 0.921 0.85 0.449 0.859 0.7 0.308 0.192
TNR 0.973 0.979 1 0.979 0.995 1 0.983 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.679 3.774 3.978 3.669 3.759 3.147 3.745 3.784 3.583
ALL 3.014 2.973 2.312 2.983 2.879 2.482 3.009 2.933 2.587
Scenario 3 LRV
Number of Patients: 120
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.883 0.576 0.936 0.861 0.453 0.88 0.697 0.319 0.739
TNR 0.987 0.984 1 0.987 0.996 1 0.987 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.643 3.72 4.149 3.691 3.768 3.456 3.715 3.705 3.178
ALL 2.99 2.922 2.248 2.985 3.127 2.074 2.819 2.911 2.537
Scenario 3 LRV
Number of Patients: 130
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.899 0.595 0.92 0.872 0.468 0.824 0.777 0.328 0.605
TNR 0.98 0.986 1 0.98 0.998 1 0.989 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.703 3.783 3.798 3.588 3.761 3.405 3.495 3.675 4.274
ALL 2.936 2.958 1.412 2.932 3.041 2.638 2.83 2.989 2.022
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Scenario 3 LRV
Number of Patients: 140
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.913 0.602 0.938 0.886 0.476 0.937 0.77 0.338 0.872
TNR 0.997 0.985 1 0.997 0.997 1 0.997 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB
ALL





Number of Patients: 60
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.91 0.759 0.554 0.774 0.619 0.225 0.603 0.447 0
TNR 0.998 0.995 1 0.998 0.997 1 0.999 0.999 1
SFE 0 0.001 0 0 0 0 0 0 0
SUB 3.574 3.394 3.701 3.604 3.573 3.844 3.627 3.696 3.745
ALL 1.428 1.508 1.682 1.436 1.461 1.18 1.443 1.412 1.836
Scenario 4 LRV
Number of Patients: 70
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.956 0.796 0.44 0.867 0.656 0.005 0.629 0.469 0
TNR 0.998 0.995 1 0.998 0.997 1 0.999 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.617 3.35 3.777 3.582 3.573 3.352 3.633 3.668 3.408
ALL 1.373 1.487 2.131 1.365 1.503 1.551 1.468 1.443 1.308
Scenario 4 LRV
Number of Patients: 80
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.986 0.799 0.885 0.935 0.657 0.413 0.683 0.464 0.073
TNR 0.998 0.995 1 0.998 0.997 1 0.999 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.612 3.361 3.995 3.601 3.525 3.825 3.671 3.628 3.758
ALL 1.405 1.451 2.255 1.462 1.35 1.95 1.463 1.358 0.916
Scenario 4 LRV
Number of Patients: 90
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.993 0.789 1 0.961 0.632 1 0.685 0.425 1
TNR 0.999 0.996 0.964 0.999 0.998 0.964 0.999 0.999 0.964
SFE 0 0 0 0 0 0 0 0 0
SUB 3.514 3.363 3.765 3.607 3.579 3.997 3.617 3.681 3.496
ALL 1.415 1.457 1.349 1.409 1.472 1.561 1.462 1.484 1.846
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Scenario 4 LRV
Number of Patients: 100
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.994 0.797 1 0.945 0.644 0.999 0.746 0.434 0.261
TNR 0.999 0.996 1 0.999 0.998 1 0.999 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.609 3.398 3.669 3.548 3.57 4.33 3.706 3.644 4
ALL 1.54 1.442 1.042 1.421 1.339 1.077 1.375 1.477 1.171
Scenario 4 LRV
Number of Patients: 110
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.995 0.826 1 0.976 0.668 1 0.855 0.447 0.989
TNR 0.998 0.996 1 0.998 0.998 1 0.999 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.598 3.391 3.338 3.613 3.549 3.321 3.613 3.568 3.796
ALL 1.457 1.516 1.848 1.487 1.322 0.955 1.486 1.275 1.636
Scenario 4 LRV
Number of Patients: 120
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.996 0.828 1 0.986 0.676 1 0.876 0.47 1
TNR 0.999 0.996 1 0.999 0.998 1 0.999 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.589 3.317 2.716 3.639 3.547 3.927 3.559 3.628 3.88
ALL 1.45 1.299 0.442 1.387 1.411 1.724 1.412 1.39 1.624
Scenario 4 LRV
Number of Patients: 130
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.998 0.833 1 0.987 0.689 1 0.877 0.478 0.993
TNR 0.999 0.996 0.964 0.999 0.998 0.964 0.999 1 0.969
SFE 0 0 0 0 0 0 0 0 0
SUB 3.497 3.175 3.202 3.459 3.581 2.617 3.579 3.55
ALL 1.634 1.513 2.677 1.305 1.502 1.313 1.335 1.471 2.66
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Scenario 4 LRV
Number of Patients: 140
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 1 0.841 1 1 0.675 1 0.92 0.45 1
TNR 0.998 0.996 0.964 0.998 0.999 0.974 0.999 1 0.992
SFE 0 0 0 0 0 0 0 0 0
SUB
ALL
Table 12: Scenario 4, δ = 0.5
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Scenario 4 LRV
Number of Patients: 60
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.855 0.601 0.336 0.753 0.452 0 0.541 0.287 0
TNR 0.999 0.997 1 0.999 0.999 1 0.999 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.706 3.54 3.79 3.641 3.701 4.034 3.646 3.697 3.857
ALL 1.408 1.394 0.785 1.437 1.41 1.98 1.418 1.509 0.865
Scenario 4 LRV
Number of Patients: 70
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.928 0.65 0.193 0.851 0.486 0 0.568 0.301 0
TNR 0.998 0.998 1 0.998 0.999 1 0.999 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.646 3.57 3.302 3.687 3.682 3.615 3.679 3.755 3.501
ALL 1.382 1.343 1.039 1.449 1.341 1.21 1.462 1.378 1.342
Scenario 4 LRV
Number of Patients: 80
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.977 0.662 0.652 0.89 0.495 0.186 0.586 0.303 0.006
TNR 0.999 0.998 1 0.999 0.999 1 0.999 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.674 3.525 3.763 3.65 3.537 3.334 3.69 3.724 3.632
ALL 1.452 1.433 1.951 1.417 1.345 1.863 1.432 1.436 1.592
Scenario 4 LRV
Number of Patients: 90
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.982 0.653 1 0.938 0.47 1 0.629 0.272 1
TNR 0.999 0.998 0.964 0.999 0.999 0.964 1 1 0.964
SFE 0 0 0 0 0 0 0 0 0
SUB 3.683 3.575 4.183 3.67 3.687 4.021 3.637 3.692 4.462
ALL 1.423 1.383 1.702 1.33 1.434 1.453 1.468 1.41 1.355
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Scenario 4 LRV
Number of Patients: 100
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.989 0.67 1 0.932 0.489 0.805 0.692 0.281 0.004
TNR 0.999 0.998 1 0.999 0.999 1 0.999 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.644 3.553 4.073 3.678 3.679 3.87 3.638 3.683 4.08
ALL 1.411 1.407 1.555 1.426 1.428 1.675 1.37 1.426 1.195
Scenario 4 LRV
Number of Patients: 110
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.99 0.701 1 0.961 0.511 1 0.811 0.285 0.888
TNR 0.999 0.998 1 0.999 0.999 1 0.999 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.681 3.592 3.561 3.648 3.611 2.799 3.682 3.698 3.301
ALL 1.369 1.424 0.957 1.407 1.46 2.053 1.469 1.455 1.595
Scenario 4 LRV
Number of Patients: 120
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.989 0.714 1 0.979 0.538 1 0.839 0.326 0.994
TNR 0.999 0.997 1 0.999 0.999 1 0.999 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.63 3.594 4.071 3.651 3.635 3.851 3.744 3.756 3.432
ALL 1.337 1.355 2.481 1.511 1.361 1.225 1.46 1.389 3.454
Scenario 4 LRV
Number of Patients: 130
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.996 0.734 1 0.976 0.559 1 0.856 0.339 0.974
TNR 0.999 0.998 0.964 0.999 0.999 0.967 0.999 1 0.99
SFE 0 0 0 0 0 0 0 0 0
SUB 3.546 3.505 4.782 3.528 3.589 3.618 3.615
ALL 1.311 1.317 -0.397 1.456 1.464 1.639 1.314 1.372 3.094
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Scenario 4 LRV
Number of Patients: 140
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.999 0.731 1 0.998 0.532 1 0.889 0.306 1
TNR 0.999 0.998 0.973 0.999 0.999 0.983 0.999 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB
ALL
Table 13: Scenario 4, δ = 0.7
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Scenario 4 LRV
Number of Patients: 60
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.818 0.356 0 0.683 0.219 0 0.416 0.108 0
TNR 0.999 0.999 1 0.999 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.72 3.679 3.792 3.71 3.756 3.937 3.667 3.768 3.903
ALL 1.395 1.362 1.803 1.414 1.407 1.665 1.4 1.461 1.642
Scenario 4 LRV
Number of Patients: 70
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.899 0.394 0 0.784 0.244 0 0.483 0.113 0
TNR 0.999 0.999 1 0.999 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.694 3.721 3.174 3.723 3.663 3.615 3.725 3.679 4.039
ALL 1.39 1.432 1.691 1.369 1.466 1.642 1.441 1.435 1.189
Scenario 4 LRV
Number of Patients: 80
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.944 0.426 0.261 0.829 0.258 0.021 0.519 0.114 0
TNR 1 0.999 1 1 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.74 3.615 3.528 3.72 3.696 4.053 3.677 3.703 3.83
ALL 1.422 1.424 1.492 1.425 1.428 1.232 1.39 1.374 1.765
Scenario 4 LRV
Number of Patients: 90
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.945 0.406 1 0.894 0.244 1 0.487 0.108 0.973
TNR 1 0.999 0.964 1 1 0.965 1 1 0.979
SFE 0 0 0 0 0 0 0 0 0
SUB 3.705 3.677 3.845 3.682 3.673 3.851 3.751 3.685 3.285
ALL 1.429 1.377 1.556 1.45 1.458 1.81 1.387 1.372 1.69
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Scenario 4 LRV
Number of Patients: 100
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.958 0.441 0.83 0.893 0.26 0.039 0.646 0.108 0
TNR 1 1 1 1 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.732 3.723 3.657 3.767 3.766 3.812 3.739 3.72
ALL 1.436 1.501 1.589 1.426 1.507 1.317 1.435 1.463 1.437
Scenario 4 LRV
Number of Patients: 110
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.98 0.472 1 0.932 0.274 0.927 0.717 0.115 0.491
TNR 1 0.999 1 1 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.698 3.694 3.196 3.686 3.703 3.359 3.762 3.728 3.321
ALL 1.389 1.42 0.609 1.359 1.362 0.342 1.339 1.203 0.931
Scenario 4 LRV
Number of Patients: 120
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.979 0.511 1 0.959 0.324 0.998 0.783 0.153 0.956
TNR 1 0.999 1 1 0.999 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.787 3.647 3.957 3.726 3.687 3.589 3.828 3.72
ALL 1.358 1.402 2.16 1.45 1.436 0.95 1.544 1.392 1.439
Scenario 4 LRV
Number of Patients: 130
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.984 0.54 1 0.955 0.346 0.986 0.776 0.162 0.903
TNR 1 0.999 0.967 1 1 0.983 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.752 3.652 3.651 3.795 3.582 3.598
ALL 1.323 1.325 3.546 1.513 1.452 0.023 1.47 1.27 1.701
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Scenario 4 LRV
Number of Patients: 140
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.995 0.521 1 0.995 0.32 1 0.786 0.145 0.947
TNR 1 1 0.996 1 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB
ALL





Number of Patients: 60
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.848 0.456 0.368 0.657 0.326 0.147 0.399 0.198 0
TNR 1 0.998 1 1 0.999 1 1 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.762 2.602 3.505 3.749 2.653 3.402 3.77 2.549 3.766
ALL 1.984 1.96 1.961 2.015 1.912 2.188 1.932 2.049 1.735
Scenario 5 LRV
Number of Patients: 70
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.843 0.466 0.413 0.703 0.335 0.245 0.507 0.2 0.143
TNR 1 0.998 0.797 1 0.999 0.819 1 0.999 0.979
SFE 0 0 0 0 0 0 0 0 0
SUB 3.772 2.575 3.47 3.785 2.445 3.444 3.74 2.577 3.79
ALL 2.001 2.006 2.065 1.913 1.981 2.096 2.062 2.008 2.503
Scenario 5 LRV
Number of Patients: 80
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.888 0.428 0.656 0.823 0.295 0.363 0.53 0.164 0.191
TNR 1 0.998 1 1 0.999 1 1 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.773 2.494 4.001 3.751 2.374 3.82 3.739 2.445 3.879
ALL 1.949 2.024 3.017 2.034 2.008 2.992 2.044 2.069 1.971
Scenario 5 LRV
Number of Patients: 90
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.946 0.429 0.981 0.87 0.275 0.947 0.586 0.147 0.668
TNR 1 0.998 0.763 1 0.999 0.785 1 0.999 0.967
SFE 0 0 0 0 0 0 0 0 0
SUB 3.769 2.579 3.689 3.709 2.68 3.647 3.735 2.536 3.217
ALL 2.029 1.943 1.692 1.921 1.984 1.983 1.966 2.004 2.047
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Scenario 5 LRV
Number of Patients: 100
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.969 0.486 0.667 0.92 0.316 0.667 0.7 0.156 0.565
TNR 1 0.998 1 1 0.999 1 1 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.791 2.545 3.822 3.779 2.312 3.504 3.795 2.262 3.731
ALL 1.98 2.004 2.345 2.022 2.039 2.479 2.044 2.047 1.747
Scenario 5 LRV
Number of Patients: 110
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.957 0.463 1 0.903 0.304 0.82 0.69 0.139 0.094
TNR 1 0.998 1 1 0.999 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.626 2.497 3.472 3.724 2.546 4.012 3.705 2.374 3.39
ALL 1.93 1.963 1.292 1.976 1.998 2.331 1.984 1.99 1.132
Scenario 5 LRV
Number of Patients: 120
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.983 0.468 1 0.933 0.308 1 0.803 0.152 0.741
TNR 1 0.998 1 1 0.999 1 1 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.723 2.527 4.277 3.787 2.499 3.544 3.79 2.569 3.836
ALL 1.986 1.974 2.802 2.066 1.936 0.673 1.942 2.04 2.673
Scenario 5 LRV
Number of Patients: 130
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.987 0.498 1 0.957 0.325 0.972 0.823 0.15 0.749
TNR 1 0.998 0.819 1 0.999 0.891 1 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.679 2.41 2.799 3.649 2.433 1.645 3.668 2.487 2.292
ALL 2.14 2.082 2.721 2.034 1.826 2.295 1.911 1.88 2.933
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Scenario 5 LRV
Number of Patients: 140
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.99 0.481 0.865 0.937 0.315 0.72 0.813 0.143 0.402
TNR 1 0.998 1 1 0.999 1 1 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB
ALL
Table 15: Scenario 5, δ = 0.5
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Scenario 5 LRV
Number of Patients: 60
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.818 0.276 0.201 0.627 0.173 0.036 0.319 0.086 0
TNR 1 0.999 1 1 0.999 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.761 2.709 3.757 3.778 2.62 3.456 3.762 2.523 4.192
ALL 1.968 2.003 2.133 2 2.003 2.012 1.909 1.945 2.094
Scenario 5 LRV
Number of Patients: 70
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.807 0.303 0.247 0.676 0.187 0.183 0.437 0.086 0.037
TNR 1 0.999 0.816 1 0.999 0.964 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.736 2.535 3.815 3.771 2.522 3.62 3.756 2.327 3.436
ALL 2.027 2.004 2.375 1.894 2.01 1.741 2.004 2.037 2.127
Scenario 5 LRV
Number of Patients: 80
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.858 0.27 0.466 0.767 0.16 0.2 0.457 0.067 0.156
TNR 1 0.999 1 1 0.999 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.752 2.461 3.764 3.731 2.454 3.874 3.751 2.275 3.376
ALL 1.986 2.053 1.621 2.018 1.961 2.517 1.97 1.958 1.66
Scenario 5 LRV
Number of Patients: 90
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.926 0.253 0.951 0.84 0.146 0.749 0.56 0.07 0.504
TNR 1 0.999 0.785 1 0.999 0.935 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.729 2.682 3.875 3.772 2.681 3.813 3.684 2.553 3.8
ALL 2.027 1.868 1.593 1.949 2.03 2.443 2.003 2.049 2.069
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Scenario 5 LRV
Number of Patients: 100
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.962 0.304 0.667 0.897 0.166 0.667 0.647 0.061 0.273
TNR 1 0.999 1 1 0.999 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.783 2.518 3.136 3.691 2.3 3.351 3.75 2.299 3.9
ALL 2.014 2.099 1.983 2.004 2.024 2.044 1.977 1.989 2.618
Scenario 5 LRV
Number of Patients: 110
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.953 0.3 0.999 0.877 0.157 0.24 0.63 0.056 0.005
TNR 1 0.999 1 1 0.999 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.707 2.629 3.007 3.722 2.548 4.15 3.749 2.567 3.624
ALL 2.03 1.927 1.011 1.97 2.014 3.328 1.916 1.957 0.729
Scenario 5 LRV
Number of Patients: 120
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.983 0.309 1 0.917 0.171 0.963 0.767 0.069 0.615
TNR 1 0.999 1 1 0.999 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.775 2.695 4.278 3.787 2.587 3.78 3.85 2.439 4.438
ALL 2.06 1.935 0.611 1.917 2.062 2.559 1.928 1.868 2.356
Scenario 5 LRV
Number of Patients: 130
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.983 0.337 0.988 0.94 0.178 0.908 0.767 0.07 0.669
TNR 1 0.999 0.871 1 0.999 0.99 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.722 2.669 2.226 3.803 2.753 2.77 3.803 2.591 3.369
ALL 1.889 2.062 3.994 1.848 1.791 2.181 2.054 1.921 2.542
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Scenario 5 LRV
Number of Patients: 140
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.98 0.33 0.76 0.927 0.177 0.543 0.78 0.059 0.259
TNR 1 0.999 1 1 0.999 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB
ALL
Table 16: Scenario 5, δ = 0.7
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Scenario 5 LRV
Number of Patients: 60
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.708 0.094 0.069 0.558 0.047 0 0.245 0.017 0
TNR 1 1 1 1 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.74 2.793 3.427 3.729 2.621 3.865 3.778 2.152 3.473
ALL 1.959 2.046 1.892 1.922 1.951 2.108 1.938 2.022 2.025
Scenario 5 LRV
Number of Patients: 70
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.762 0.109 0.168 0.616 0.051 0.03 0.383 0.016 0
TNR 1 1 0.998 1 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.728 2.494 3.079 3.743 2.516 3.946 3.798 2.379 3.649
ALL 1.998 2.023 1.824 2.019 1.979 1.892 1.963 2.026 2.543
Scenario 5 LRV
Number of Patients: 80
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.843 0.097 0.193 0.71 0.039 0.156 0.36 0.009 0.009
TNR 1 1 1 1 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.747 2.497 3.839 3.774 2.51 3.186 3.837 1.909 3.557
ALL 2.043 1.962 1.891 1.946 2.05 1.927 2.004 1.939 1.451
Scenario 5 LRV
Number of Patients: 90
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.902 0.099 0.689 0.75 0.054 0.489 0.47 0.022 0.187
TNR 1 1 1 1 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.756 2.862 4.029 3.783 2.777 3.378 3.724 2.491
ALL 2.033 2.041 1.899 2.018 1.972 1.427 1.935 1.963 2.62
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Scenario 5 LRV
Number of Patients: 100
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.945 0.111 0.665 0.867 0.042 0.375 0.573 0.01 0.002
TNR 1 1 1 1 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.71 2.564 3.774 3.734 2.455 3.574 3.721 2.245 3.346
ALL 1.994 2.057 2.714 1.978 1.988 2.394 2.07 1.986 2.178
Scenario 5 LRV
Number of Patients: 110
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.95 0.109 0.293 0.837 0.041 0.002 0.587 0.01 0
TNR 1 1 1 1 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.753 2.657 2.796 3.761 2.689 3.804 3.689 2.805 4.549
ALL 1.974 1.999 2.738 1.928 2.044 2.658 1.988 1.943 2.839
Scenario 5 LRV
Number of Patients: 120
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.973 0.128 0.967 0.9 0.056 0.637 0.71 0.013 0.309
TNR 1 0.999 1 1 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.717 2.606 3.352 3.756 2.396 4.44 3.799 2.093 3.279
ALL 2.138 2.124 1.805 1.902 2.023 2.573 1.921 1.884 1.92
Scenario 5 LRV
Number of Patients: 130
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.977 0.138 0.928 0.923 0.061 0.735 0.663 0.016 0.548
TNR 1 0.999 1 1 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.783 2.539 2.611 3.689 2.614 2.076 3.787 1.983
ALL 1.766 1.88 0.602 2.065 1.979 2.116 1.968 1.899 1.422
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Scenario 5 LRV
Number of Patients: 140
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.97 0.14 0.529 0.897 0.051 0.31 0.73 0.01 0.057
TNR 1 1 1 1 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB
ALL





Number of Patients: 60
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.822 0.84 0.942 0.787 0.742 0.843 0.611 0.589 0.61
TNR 0.998 0.998 0.454 0.998 0.998 0.54 0.999 0.999 0.718
SFE 0 0 0 0 0 0 0 0 0
SUB 3.546 3.428 3.142 3.534 3.6 3.145 3.573 3.678 3.45
ALL 3.166 3.168 3.269 3.184 3.198 3.269 3.106 3.197 3.272
Scenario 6 LRV
Number of Patients: 70
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.863 0.855 0.969 0.847 0.759 0.844 0.742 0.599 0.619
TNR 0.998 0.998 0.698 0.998 0.999 0.934 0.999 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.593 3.41 3.707 3.564 3.562 3.631 3.615 3.677 4.104
ALL 3.202 3.155 3.179 3.168 3.184 3.139 3.177 3.219 3.065
Scenario 6 LRV
Number of Patients: 80
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.88 0.849 0.803 0.841 0.748 0.797 0.707 0.595 0.32
TNR 0.998 0.998 1 0.998 0.999 1 0.999 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.564 3.444 3.816 3.627 3.621 3.422 3.663 3.647 4.159
ALL 3.158 3.127 3.52 3.173 3.119 3.327 3.162 3.158 2.76
Scenario 6 LRV
Number of Patients: 90
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.884 0.877 0.83 0.851 0.785 0.814 0.741 0.624 0.803
TNR 0.998 0.998 0.916 0.999 0.998 0.967 0.999 0.999 0.993
SFE 0 0 0 0 0 0 0 0 0
SUB 3.606 3.44 3.562 3.563 3.525 3.405 3.614 3.647 3.899
ALL 3.162 3.179 2.856 3.212 3.219 3.35 3.178 3.133 3.517
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Scenario 6 LRV
Number of Patients: 100
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.892 0.876 0.885 0.875 0.777 0.829 0.781 0.615 0.773
TNR 0.999 0.998 1 0.999 0.999 1 0.999 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.553 3.397 3.563 3.586 3.565 3.513 3.6 3.618 4.284
ALL 3.319 3.139 2.734 3.206 3.099 4.108 3.154 3.126 3.745
Scenario 6 LRV
Number of Patients: 110
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.884 0.886 0.8 0.876 0.795 0.8 0.782 0.629 0.8
TNR 0.999 0.998 1 0.999 0.999 1 0.999 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.562 3.441 3.839 3.592 3.477 3.374 3.528 3.721 3.233
ALL 3.192 3.167 2.583 3.222 3.14 3.035 3.082 3.102 4.258
Scenario 6 LRV
Number of Patients: 120
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.886 0.882 0.89 0.86 0.791 0.821 0.803 0.625 0.8
TNR 0.999 0.998 1 0.999 0.999 1 0.999 0.999 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.461 3.426 3.487 3.582 3.678 3.756 3.534 3.697 4.196
ALL 3.245 3.111 2.273 3.221 3.178 3.667 3.119 3.183 2.363
Scenario 6 LRV
Number of Patients: 130
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.891 0.886 0.875 0.87 0.797 0.858 0.827 0.646 0.826
TNR 0.999 0.998 0.751 0.999 0.999 0.893 0.999 1 0.981
SFE 0 0 0 0 0 0 0 0 0
SUB 3.603 3.51 2.261 3.449 3.447 3.404 3.632 3.3 3.183
ALL 3.294 3.288 4.059 3.262 3.153 4.711 3.227 3.237 3.597
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Scenario 6 LRV
Number of Patients: 140
δ = 0.5
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.898 0.892 0.975 0.89 0.8 0.905 0.805 0.635 0.86
TNR 0.999 0.998 0.497 0.999 0.999 0.677 0.999 0.999 0.805
SFE 0 0 0 0 0 0 0 0 0
SUB
ALL
Table 18: Scenario 6, δ = 0.5
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Scenario 6 LRV
Number of Patients: 60
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.782 0.721 0.901 0.755 0.589 0.735 0.534 0.414 0.495
TNR 0.999 0.999 0.533 0.999 0.999 0.703 0.999 1 0.958
SFE 0 0 0 0 0 0 0 0 0
SUB 3.629 3.51 3.595 3.647 3.627 3.452 3.672 3.692 3.737
ALL 3.179 3.123 3.538 3.211 3.176 2.844 3.192 3.148 3.334
Scenario 6 LRV
Number of Patients: 70
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.837 0.745 0.876 0.818 0.611 0.688 0.677 0.436 0.491
TNR 0.998 0.999 0.922 0.999 0.999 1 0.999 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.556 3.515 3.258 3.595 3.675 3.718 3.651 3.707 3.863
ALL 3.15 3.18 2.999 3.166 3.194 2.64 3.211 3.186 2.573
Scenario 6 LRV
Number of Patients: 80
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.847 0.751 0.802 0.791 0.622 0.737 0.675 0.452 0.241
TNR 0.999 0.999 1 0.999 0.999 1 0.999 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.578 3.525 3.747 3.632 3.651 3.689 3.622 3.731 3.785
ALL 3.142 3.154 3.838 3.146 3.159 3.387 3.192 3.2 3.729
Scenario 6 LRV
Number of Patients: 90
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.853 0.789 0.816 0.828 0.662 0.803 0.708 0.467 0.8
TNR 0.999 0.998 0.963 0.999 0.999 0.993 0.999 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.574 3.511 3.66 3.588 3.634 3.348 3.598 3.754 4.17
ALL 3.173 3.208 3.06 3.189 3.209 3.164 3.213 3.163 3.069
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Scenario 6 LRV
Number of Patients: 100
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.857 0.787 0.857 0.828 0.657 0.804 0.732 0.464 0.707
TNR 0.999 0.999 1 0.999 0.999 1 0.999 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.627 3.553 3.704 3.595 3.666 3.503 3.679 3.684 3.613
ALL 3.11 3.136 3.589 3.118 3.165 3.427 3.169 3.228 2.946
Scenario 6 LRV
Number of Patients: 110
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.866 0.808 0.8 0.853 0.676 0.8 0.752 0.493 0.8
TNR 0.999 0.999 1 0.999 0.999 1 0.999 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.513 3.509 3.748 3.576 3.566 4.144 3.597 3.666 4.151
ALL 3.154 3.241 4.027 3.14 3.231 2.995 3.2 3.214 3.238
Scenario 6 LRV
Number of Patients: 120
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.863 0.808 0.846 0.84 0.683 0.8 0.776 0.494 0.8
TNR 0.999 0.999 1 0.999 0.999 1 0.999 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.535 3.517 4.131 3.434 3.672 3.798 3.515 3.688 4.332
ALL 3.19 3.172 3.213 3.077 3.253 3.017 3.191 3.145 4.186
Scenario 6 LRV
Number of Patients: 130
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.872 0.818 0.862 0.852 0.706 0.839 0.81 0.522 0.809
TNR 0.999 0.999 0.892 0.999 0.999 0.938 0.999 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.516 3.617 3.514 3.701 3.078 3.597 3.734 3.671
ALL 3.21 3.191 2.57 3.083 3.178 2.98 3.167 3.184 5.024
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Scenario 6 LRV
Number of Patients: 140
δ = 0.7
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.873 0.824 0.928 0.861 0.701 0.877 0.764 0.507 0.826
TNR 0.999 0.999 0.653 0.999 0.999 0.749 0.999 1 0.94
SFE 0 0 0 0 0 0 0 0 0
SUB
ALL
Table 19: Scenario 6, δ = 0.7
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Scenario 6 LRV
Number of Patients: 60
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.739 0.483 0.769 0.694 0.336 0.567 0.424 0.192 0.337
TNR 0.999 0.999 0.817 0.999 1 0.989 0.999 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.622 3.666 3.654 3.644 3.694 3.403 3.709 3.744 3.929
ALL 3.201 3.131 3.389 3.201 3.185 3.241 3.213 3.13 2.901
Scenario 6 LRV
Number of Patients: 70
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.777 0.525 0.675 0.736 0.375 0.516 0.556 0.217 0.345
TNR 0.999 1 1 0.999 1 1 0.999 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.59 3.674 3.726 3.628 3.71 4.014 3.656 3.754 3.539
ALL 3.22 3.228 2.534 3.144 3.17 3.188 3.132 3.139 4.064
Scenario 6 LRV
Number of Patients: 80
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.784 0.564 0.8 0.733 0.411 0.323 0.598 0.246 0.098
TNR 0.999 1 1 0.999 1 1 0.999 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.677 3.675 3.843 3.648 3.686 4.154 3.672 3.764 3.786
ALL 3.186 3.188 3.24 3.1 3.174 2.971 3.138 3.159 2.612
Scenario 6 LRV
Number of Patients: 90
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.812 0.605 0.801 0.798 0.437 0.8 0.649 0.25 0.8
TNR 0.999 0.999 1 0.999 1 1 0.999 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.628 3.608 3.523 3.68 3.679 4.331 3.607 3.738 3.951
ALL 3.224 3.126 3.211 3.18 3.211 3.797 3.116 3.149 2.599
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Scenario 6 LRV
Number of Patients: 100
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.828 0.611 0.807 0.777 0.443 0.799 0.646 0.244 0.535
TNR 0.999 1 1 0.999 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.65 3.69 4.077 3.689 3.675 4.047 3.695 3.787 4.05
ALL 3.159 3.092 3.346 3.145 3.141 3.481 3.145 3.193 3.937
Scenario 6 LRV
Number of Patients: 110
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.833 0.641 0.8 0.824 0.482 0.8 0.69 0.284 0.798
TNR 0.999 0.999 1 0.999 1 1 0.999 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.573 3.579 4.158 3.577 3.759 4.127 3.568 3.743 4.388
ALL 3.198 3.194 1.834 3.241 3.208 3.588 3.188 3.135 2.798
Scenario 6 LRV
Number of Patients: 120
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.834 0.656 0.8 0.804 0.49 0.8 0.712 0.29 0.79
TNR 0.999 0.999 1 0.999 1 1 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.587 3.68 3.549 3.643 3.67 3.603 3.545 3.737 3.302
ALL 3.198 3.16 3.234 3.247 3.172 4.446 3.254 3.131 3.513
Scenario 6 LRV
Number of Patients: 130
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.851 0.686 0.84 0.837 0.529 0.819 0.781 0.339 0.772
TNR 0.999 0.999 0.954 0.999 1 1 0.999 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB 3.696 3.695 3.927 3.56 3.737 3.808 3.634 3.63 3.157
ALL 3.219 3.139 3.186 3.155 3.158 3.445 3.104 3.124 3.707
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Scenario 6 LRV
Number of Patients: 140
δ = 0.9
2.37 2.7 3.08
ASID LR GUIDE ASID LR GUIDE ASID LR GUIDE
TPR 0.846 0.683 0.868 0.829 0.522 0.83 0.717 0.313 0.741
TNR 0.999 0.999 0.768 0.999 1 0.942 1 1 1
SFE 0 0 0 0 0 0 0 0 0
SUB
ALL
Table 20: Scenario 6, δ = 0.9
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